

Review

BDNF function and intracellular signaling in neurons

Tadahiro Numakawa¹, Shingo Suzuki^{2,3}, Emi Kumamaru¹,
Naoki Adachi^{1,4}, Misty Richards^{1,5} and Hiroshi Kunugi^{1,4}

¹Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan, ²Medical Top Track (MTT) Program, Medical Research Institute, Tokyo Medical and Dental University, ³Department of Molecular Neuroscience, Medical Research Institute, Tokyo Medical and Dental University, ⁴CREST, JST, Saitama and ⁵Albany Medical College, Albany, USA

Summary. Brain-derived neurotrophic factor (BDNF) and its receptor, TrkB, are broadly expressed in the developing and adult mammalian brain. BDNF/TrkB-stimulated intracellular signaling is critical for neuronal survival, morphogenesis, and plasticity. It is well known that binding of BDNF to TrkB elicits various intracellular signaling pathways, including mitogen-activated protein kinase/extracellular signal-regulated protein kinase (MAPK/ERK), phospholipase C γ (PLC γ), and phosphoinositide 3-kinase (PI3K) pathways, and that BDNF exerts biological effects on neurons via activation of similar mechanisms. In addition to TrkB, a low-affinity receptor p75 is also involved in neuronal survival and plasticity. BDNF affects neurons positively or negatively through various intracellular signaling pathways triggered by activation of TrkB or p75. From a clinical standpoint, roles of BDNF have been implicated in the pathophysiology of various brain diseases. The stress-induced steroid hormone, glucocorticoid, and BDNF are putatively associated with the pathophysiology of depression. Recent reports, including our studies, demonstrate possible crosstalk between glucocorticoid- and BDNF/TrkB-mediated signaling. Here, we present a broad overview of the current knowledge concerning BDNF action and associated intracellular signaling as it relates to neuronal protection, synaptic function, and morphological change. Furthermore, understanding the secretion and intracellular dynamics of BDNF proteins is critical as the fate of secreted BDNF may contribute to differences in neuronal response.

Key words: Synaptic function, Morphological changes, Cholesterol metabolism, Mental illness, BDNF regulator, BDNF secretion

Introduction

Neurotrophins, namely nerve growth factor (NGF), BDNF, neurotrophin-3 (NT-3), and NT-4/5, bind to high-affinity Trk receptors, as well as to a common low-affinity p75 receptor. Binding of NGF to TrkA, BDNF and NT-4/5 to TrkB, or of NT-3 to TrkC (weakly to TrkB) leads to activation of various intracellular signaling pathways. It is well known that MAPK/ERK, PLC γ , and PI3K pathways are stimulated after Trk activation (Huang and Reichardt, 2003). Beyond the promotion of cell differentiation, nerve growth, and neuronal survival, the neurotrophin family plays multiple roles in regulating neuronal structure and function in the developing and mature nervous system via activation of various pathways, including the three signaling cascades mentioned above.

BDNF/TrkB-stimulated signaling is necessary for survival and morphogenesis of CNS neurons. Furthermore, it is widely accepted that BDNF plays a critical role in neuronal plasticity. In this article, a broad review of the current literature concerning BDNF-dependent intracellular signaling is described. We focus on the role of BDNF in neuronal survival, synaptic function, and morphological change, in addition to the importance of secretion or intracellular transport of this factor. BDNF is translated as a precursor protein (proBDNF), subsequently proteolytically cleaved to generate a small mature protein (mBDNF). The p75 neurotrophin receptor binds to pro-neurotrophin with high-affinity (Lee et al., 2001) which places great importance on the amount of proBDNF secreted from

neurons. Recent reports suggest that neurons are able to release both proBDNF and mature BDNF (Yang et al., 2009). Interestingly, both low- and high-frequency neuronal activities were shown to increase extracellular levels of proBDNF, though only high-frequency activity induced tissue plasminogen activator secretion. Such secretion of tissue plasminogen activator resulted in extracellular conversion of proBDNF to mBDNF (Nagappan et al., 2009). In this article, we include several reports concerning the involvement of p75 in activity-dependent synaptic plasticity.

As expected, roles of BDNF have been implicated in the pathophysiology of various brain diseases, including depressive disorder. Indeed, many reports suggest that BDNF expression is decreased in several mental disorders, including schizophrenia, bipolar disorder, and major depression (Knable et al., 2004; Gervasoni et al., 2005; Karege et al., 2005). Interestingly, the stress hormone, glucocorticoid, is also putatively associated with the pathophysiology of depression (Watanabe et al., 1992; McEwen, 2005; Kunugi et al., 2006). Thus, it is possible that both BDNF and glucocorticoid are involved in synaptic function and the pathophysiology of depression. As a result, in this article, we provide examples concerning possible crosstalk between BDNF and glucocorticoid actions from some of our current studies.

BDNF signaling in neuronal survival

Trk receptor signaling

BDNF is critical to neuronal survival in the CNS. Moreover, in vivo application of BDNF has been shown to protect a variety of neurons from brain injury (Wu and Pardrige, 1999; Schäbitz et al., 2000). A neuroprotective effect of BDNF was observed when delivered intravenously after the onset of focal cerebral ischemia (Schäbitz et al., 2000). It has also been shown that peripherally administered BDNF plays a neuroprotective role in the brain, after BDNF is reformulated to optimize plasma pharmacokinetics with carboxyl-directed pegylation to enable transport through the blood-brain barrier by coupling to brain transport vectors (Wu and Pardrige, 1999). In vitro evidence, however, demonstrates that BDNF promotes cell survival through activation of TrkB, a high affinity receptor for BDNF. Upon activation, TrkB receptor signaling activates several small G proteins, including Ras, Rap-1, and the Cdc-42-Rac-Rho family, as well as pathways regulated by MAP kinase (MAPK), PI 3-kinase (PI3K) and phospholipase-C γ (PLC γ) (reviewed by Huang and Reichardt, 2003). Although many intracellular signaling pathways are involved in neuronal survival, the ERK/cAMP-response element binding (CREB) and PI3K/Akt pathways are among the most critical and are the pathways on which BDNF exerts its survival effects. It has been known for many years that activation of

ERK, a member of the MAPK family, is involved in BDNF-dependent survival effects (Hetman et al., 1999). In cultured hippocampal neurons, the protective effect of BDNF against glutamate toxicity is mediated by PI3K and the Ras/MAPK signaling cascades (Almeida et al., 2005). Application of norepinephrine (NE) increases BDNF and phosphorylated Trk, while this increase is prevented by ERK and PI3K inhibitors in hippocampal neurons (Chen et al., 2007). It is hypothesized that NE-induced BDNF expression follows a cyclic pathway, reminiscent of a positive feedback loop. This is because phosphorylation of the CREB protein was also increased by NE and reduced by MAPK and PI3K inhibitors, and because these inhibitors suppress phosphorylation of TrkB and CREB, respectively. N-Methyl-D-aspartate (NMDA) also promotes neuronal survival against glutamate-mediated excitotoxicity via a BDNF autocrine loop in cultured cerebellar granule cells (Zhu et al., 2005). In their system, NMDA receptor activation caused a concentration- and time-dependent activation of MAPK. This activation was blocked by an NMDA receptor antagonist and was attenuated partially by the tyrosine kinase inhibitor k252a, suggesting that activation of both NMDA and TrkB receptors are required for neuroprotection.

Recently, it has been confirmed that various survival factors, including cyclic adenosine monophosphate (cAMP), PACAP and cell depolarization elicited by high-KCl, are able to induce the activation of ERK in cerebellar granule cells (Obara et al., 2007). The literature addressing the biological effects of ERK on survival, however, demonstrates much controversy. Insulin-like growth factor 1 (IGF-1) and BDNF prevent hippocampal neurons from serum deprivation-induced cell death (Zheng and Quirion, 2004). IGF-1 and BDNF induce this neuroprotection by stimulating activation of the PI3K and MAPK pathways. Interestingly, only the inhibitor of the PI3K pathway was able to block the survival effects elicited by IGF-1 and BDNF, while an inhibitor of the MAPK pathway had no effect. Moreover, in HT22 cells that derive from a murine cell line of hippocampal origin, the pro-apoptotic function of ERK was demonstrated through persistent activation caused by glutamate-induced oxidative toxicity (Stanciu et al., 2000). To expand upon these findings, Rössler et al (2004) showed that the biological endpoint of transient versus sustained activation of ERK was strikingly different. While transient ERK activation by BDNF did not rescue HT22 cells after serum deprivation, the sustained activation of ERK by a conditionally active form of Raf-1 was effective on cell survival. In cultured cortical neurons, exposure to oxidative stress triggers a series of events including over-activation of ERK and intracellular Ca²⁺ accumulation via voltage-gated Ca²⁺ channels and ionotropic glutamate receptors, ultimately resulting in neuronal cell death (Numakawa et al., 2007). Under such oxidative stress, the ERK1/2 signal may work as a death mediator, as the MAPK pathway

inhibitor blocks the oxidative stress-induced ERK1/2 activation, Ca^{2+} overload, and consequent cell death. Comparing the neurotrophic actions of fibroblast growth factor-2 (FGF-2), IGF-1 and BDNF in hippocampal neurons, all three factors promote neuronal survival under serum-free, low-insulin conditions (Johnson-Farley, 2007). Co-treatment with either IGF-1 or BDNF enhanced FGF-2-stimulated Akt and ERK activation, though no enhancement of survival beyond that achieved by solo FGF-2 application was observed with co-treatment. As described, the MAPK/ERK signaling pathway plays a critical role in neuronal survival, while also influencing death signaling. Activation of the MAPK/ERK signaling pathway above threshold may be toxic, while basal activity of this pathway is necessary for maintenance of neuronal survival.

Many reports support a survival function to activation of the PI3K pathway (reviewed by Kaplan and Miller, 2000; Yuan and Yankner, 2000). Akt, a serine/threonine kinase, is a downstream mediator of PI3K activation (Franke et al., 1997), and the PI3K/Akt pathway is critical for neurotrophin-dependent survival in CNS neurons (reviewed by Brunet et al., 2001). Importantly, Almeida et al. (2005) showed that the PI3K/Akt pathway is involved in neuroprotection through BDNF application in cultured hippocampal neurons. In their system, PI3K inhibitors significantly decreased the activation of ERK1/2. Inhibition of MEK (MAPK/ERK kinase), on the other hand, had a minor effect on Akt activation, suggesting that the PI3K pathway is the predominant mechanism by which BDNF acts to stimulate the MAPK pathway in hippocampal neurons. The PI3K/Akt survival pathway is activated after adding ganglioside GM1 to striatal slices (Duchemin et al., 2008). PI3K activity was increased in Trk and Gab1 immunoprecipitates, and co-immunoprecipitation experiments demonstrated the association of Trk and Gab1 after GM1 application. GM1, however, did not transactivate Trk, having no effect on the subsequent release of endogenous neurotrophins (NGF, NT-3, and BDNF). This suggests that GM1 stimulates activation of PI3K, in part, through Trk and Gab1.

Endocytosis of Trk receptors is critical for neurotrophin-dependent biological functions (Grimes et al., 1996). Interestingly, blocking endocytosis in cultured CNS neurons inhibits BDNF-induced activation of Akt, but not activation of ERK (Zheng et al., 2008). As expected, such endocytosis-dependent activation of Akt is important for survival-promoting effects of BDNF. Overall, in contrast to activation of the MAPK/ERK pathway, there is accumulating evidence that activation of the PI3K/Akt pathway acts as the predominant survival-promoting signal.

BDNF has been implicated in the pathophysiology of neuroprotection and thought of as a potential treatment for neurodegeneration. Cystamine (CYS), an anti-oxidant and anti-apoptotic compound, increased

BDNF protein levels in frontal cortex tissue seven days after treatment (Pillai et al., 2008). CYS protects cortical neurons through a mechanism involving TrkB receptor activation, and a signaling pathway involving PI3K and MAPK/ERK. Leptin, an adipose hormone, protects against delayed neuronal cell death in hippocampal CA1 following transient global cerebral ischemia (Zhang and Chen, 2008). Leptin increases expression of BDNF and the phosphorylation of Akt and ERK1/2 in the CA1 region after ischemia. Furthermore, the potential therapeutic value of BDNF to Huntington's disease (HD) has been a topic of recent importance. Gharami et al. (2008) employed over-expression of BDNF in the forebrain of R6/1 mice which express a fragment of mutant huntingtin with a 116-glutamine tract. Indeed, the BDNF overexpression increased TrkB/Akt signaling activity in the striatum, ameliorated motor dysfunction, and reversed brain weight loss in R6/1 mice.

Trk receptors can also stimulate the PLC γ pathway, which is known to activate the transient receptor potential cation channel (TRPC) (reviewed by Clapham, 2003). Recently, Jia et al., (2007) showed that two members of the TRPC subfamily, TRPC3 and 6, prevented cerebellar granule neurons (CGN) from cell death in cultures and supported survival of CGN in rat brain. It is well known that activation of PLC γ is stimulated by BDNF hydrolyses of PtdIns (4, 5)P₂ to generate inositol tris-phosphate (IP₃) and diacylglycerol, where IP₃ is required for intracellular Ca^{2+} channel activation (reviewed by Huang and Reichardt, 2003). BDNF induced an intracellular Ca^{2+} increase via IP₃-sensitive Ca^{2+} channels in cultured cortical neurons (Numakawa et al., 2002a,b). Notably, increases in intracellular Ca^{2+} consequently regulate BDNF expression (Shieh et al., 1998; Tao et al., 1998). In addition, BDNF is produced and released in an activity-dependent manner (Hartmann et al., 2001; Balkowiec et al., 2002). Taken together, the BDNF-stimulated PLC γ /TRPC/ Ca^{2+} signaling may induce an increase in BDNF protein that serves to exert long-lasting effects on CNS neurons through the above positive feed-forward loops.

p75-dependent signals

Interestingly, a low-affinity receptor p75 binds to pro-neurotrophin with high-affinity (Lee et al., 2001). p75 is the first neurotrophin receptor to be discovered in the receptor family that includes Fas and tumor necrosis factor receptors (Chao, 1994). p75 binds all neurotrophins (including NGF, BDNF, NT-4/5, and NT-3), and transmits both positive and negative intracellular signals (reviewed by Kaplan and Miller, 2000). In early studies, the p75 receptor was found to be necessary for amplifying Trk-mediated biological effects (Hempstead et al., 1991; Davies et al., 1993; Barker and Shooter, 1994). Furthermore, transcription factor nuclear factor B, c-Jun amino-terminal kinase, and ceramide generation

were reported as p75-dependent signals (Dobrowsky et al., 1994; Carter et al., 1996; Casaccia-Bonnel et al., 1996). Authors went on to further classify roles of c-Jun amino-terminal kinase, mixed lineage kinase, and p53 in the neurotrophin-dependent neuronal cell death paradigm (Aloyz et al., 1998; Bamji et al., 1998; Friedman, 2000; Xu et al., 2001).

As described above, BDNF (mature BDNF) promotes neuronal survival via TrkB, however, mature BDNF is initially synthesized as a precursor, proBDNF. In contrast to mature proteins, proforms preferentially activate p75 to mediate neuronal cell death. Therefore, the amount of proBDNF secreted from neurons is a critical issue. Recently, Yang et al (2009) reported that neurons are able to release both proBDNF and mature BDNF. The highest levels of proBDNF were observed perinatally and declined with age, though the proform was still detectable in adulthood. In cultured hippocampal neurons, both low- and high- frequency neuronal activities increased extracellular levels of proBDNF (Nagappan et al., 2009). Surprisingly, only high-frequency activity induced tissue plasminogen activator secretion, resulting in extracellular conversion of proBDNF to matureBDNF. Boutilier et al. (2008) showed that inhibiting endocytosis reduced TrkA (receptor for NGF) activation stimulated by proNGF, but did not have the same effect on mature NGF in PC12 cells. In their system, endocytosis and cleavage appear to be essential for proNGF-induced TrkA activation. They also demonstrate that proBDNF induces activation of TrkB in cerebellar granule neurons and that proBDNF cleavage by furin and metalloproteases facilitates this effect.

BDNF signaling in synaptic function

BDNF, synaptic plasticity, and neurotransmitter release

Besides having long-term effects, including neuroprotection in the CNS, neurotrophins play a fundamental role in neuronal plasticity in the short-term (reviewed by Thoenen, 1995). For many years, it has been recognized that BDNF is essential for neuronal transmission and activity-dependent neuronal plasticity (Lessmann et al., 1994; Kang and Schuman, 1995; Levine et al., 1995; Berninger and Poo, 1996; Korte et al., 1996; Patterson et al., 1996; Li et al., 1998). Long-term potentiation (LTP) is the most studied form of synaptic plasticity. As expected, it has been widely accepted that BDNF is involved in the underlying mechanisms of LTP induction and maintenance (reviewed by Lu et al., 2008). Markedly, in addition to TrkB, p75 is also involved in activity-dependent synaptic plasticity (Rösch et al., 2005). Although LTP was unaffected in hippocampal slices prepared from p75-deficient mice, hippocampal long-term depression (LTD) was impaired. Furthermore, in the hippocampus of p75-deficient mice, the expression levels of two (RS)-

alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits, GluR2 and GluR3, were significantly altered. Moreover, proBDNF facilitates hippocampal LTD via activating p75 (Woo et al., 2005). In their system, deletion of p75 in mice selectively impaired the NMDA receptor-dependent LTD, although other forms of synaptic plasticity were not affected.

As the first step of synaptic plasticity, the release of neurotransmitters is an essential component. BDNF plays a critical role in synaptic function, especially of the glutamatergic synapses (reviewed by Carvalho et al., 2008). BDNF was reported to enhance the depolarization-evoked release of glutamate from isolated cortical and hippocampal nerve terminals (Sala et al., 1998; Jovanovic et al., 2000; Pereira et al., 2006). Jovanovic et al. (2000) showed that BDNF increased MAPK-dependent synapsin I phosphorylation and acutely facilitated evoked glutamate release. They found that a MAPK inhibitor markedly decreased synapsin I phosphorylation and concomitantly reduced neurotransmitter release. Activation of the MAPK/ERK pathway is involved in the BDNF-dependent enhancement of glutamate release evoked by depolarization in cultured cortical neurons (Matsumoto et al., 2001, 2006). PLC γ also contributes to the effects of BDNF by inducing glutamate release in cultured cerebellar and cortical neurons (Numakawa et al., 2001, 2002a). In both neuronal cultures, activation of PLC γ induced release of Ca $^{2+}$ through intracellular Ca $^{2+}$ storage reserves, while the BDNF-induced glutamate release depended on the intracellular Ca $^{2+}$ increase via IP $_3$ -sensitive Ca $^{2+}$ channels (IP $_3$ receptors). Yang et al. (2001) showed that NT3-induced potentiation of synaptic transmission at neuromuscular synapses was blocked by a PI3K inhibitor, but not by a MAPK inhibitor. Neither stimulation of Ca $^{2+}$ release from intracellular stores by IP $_3$, nor constitutively active PI3K in presynaptic terminals alone enhanced transmission. Application of IP $_3$ in neurons expressing constitutively active PI3K elicits a significant synaptic potentiation, suggesting that concomitant activation of PI3K and IP $_3$ receptors (downstream of PLC γ) is both necessary and sufficient. Interestingly, GIPC1 protein (GAIP (G Alpha Interacting Protein)-interacting protein, C terminus) binds to myosin VI (Myo6) as well as Trk receptors (Yano et al., 2006). Myosin VI (Myo6) and a Myo6-binding protein, GIPC1, were necessary for BDNF/TrkB-mediated facilitation of hippocampal LTP and BDNF-mediated enhancement of glutamate release from presynaptic terminals. Paredes et al. (2007) found that BDNF and NGF, when administered into the hippocampus (using *in vivo* techniques), evoked dopamine and glutamate release. The BDNF-induced neurotransmitter release was partially blocked by an antagonist for Trks, indicating that BDNF functions via Trk receptors to induce neurotransmitter release. In primary mesencephalic neuronal cultures, acute activation of TrkB by BDNF significantly increased

dopamine uptake (Hoover et al., 2007). The effect of BDNF on dopamine transporter activity was dependent on both the MAPK and PI3K pathways. In contrast, BDNF injection (either intracerebroventricularly or directly into the CA3 region of the hippocampus) decreased the signal amplitude and clearance rate produced by exogenously applied 5-HT (serotonin) (Benmansour et al., 2008). BDNF may play many roles in the control of neurotransmitter levels in synaptic sites. The fusion of synaptic vesicles to the plasma membrane at the nerve terminal is an essential process of exocytotic release of neurotransmitter. During exocytosis, synaptic vesicle-associated synaptic proteins (SV-proteins; synapsin I, synaptotagmin, synaptobrevin, synaptophysin, etc.) and plasma membrane-associated synaptic proteins (PM-proteins; syntaxin and SNAP25, etc.) are involved (reviewed by Südhof, 1995). BDNF application to a hippocampal slice culture obtained from P7 rats for 48 h augmented the expressions of SV-proteins (synaptotagmin, synaptophysin, and synaptobrevin, but not synapsin I), but not of PM-proteins (syntaxin and SNAP25) (Tartaglia et al., 2001). The longer stimulation with BDNF to cultured cortical neurons (prepared from E17 rats) for five days (Takei et al., 1997) or to hippocampal neurons (from E18 rats) for 7-10 days (Yamada et al., 2002) induced the increase in both SV- and PM-proteins. With regards to intracellular signaling, BDNF increases the levels of SV-proteins (synapsin I, synaptotagmin, and synaptophysin) via the PLC γ and MAPK pathways, although levels of PM-proteins (syntaxin and SNAP25) were not changed (Matsumoto et al., 2006). Interestingly, neuronal activity was necessary for the up-regulation of synapsin I, synaptotagmin, and synaptophysin expression, and PLC γ inhibitor attenuated BDNF-stimulated long-lasting MAPK/ERK activation. As BDNF potentiates glutamatergic transmission through the PLC γ pathway (Numakawa et al., 2002a), it is possible that PLC γ -mediated neuronal activity may sustain MAPK/ERK activation, resulting in an increased expression of synaptic proteins. In developing hippocampal neurons, the involvement of the MAPK/ERK pathway in BDNF-dependent upregulation of synapsin I and synaptotagmin was also confirmed (Kumamaru et al., 2008).

BDNF and ionotropic glutamate receptors

It has been widely accepted that functional alterations of ionotropic glutamate receptors, including AMPA and NMDA receptors, are involved in synaptic plasticity. Phosphorylation of AMPA receptors, or their cycling into and out of synaptic sites, is critical for mediating excitatory neurotransmission and plasticity (Carroll et al., 1999; Lissin et al., 1999; Beattie et al., 2000; Wu et al., 2004). The function of postsynaptic glutamate receptors is also regulated by BDNF. Ca²⁺ transients evoked by BDNF induce translocation of GluR1, but not NMDA receptors, to the postsynaptic

membrane in cultured cortical neurons (Nakata and Nakamura, 2007). The GluR1 trafficking regulated by BDNF occurs via IP₃ receptor- and TRPC-dependent Ca²⁺ signaling. Local regulation of mRNA translation may play an important role in synaptic plasticity as well. Schratt et al (2004) found subsets of neuronal mRNAs demonstrating enhanced translation after exposure to BDNF. Many proteins that are known to function at synapses, including Ca²⁺-calmodulin-dependent protein kinase II (CaMKII), NR1, and the postsynaptic density (PSD) scaffolding protein Homer2 were observed. BDNF regulates the translation of Homer2 locally in the synaptodendritic compartment by activating translational initiation via a mammalian target of the rapamycin (mTOR)-PI3K-dependent pathway.

BDNF acutely up-regulates GluR1, GluR2, and GluR3 subunits in cultured hippocampal neurons (Caldeira et al., 2007a). The increase in GluR1 and GluR2 protein levels was impaired by a Trk inhibitor, and by translation and transcription inhibitors. In the appropriate culture, acute stimulation with BDNF selectively increased the level of GluR1 associated with the plasma membrane. Furthermore, BDNF induced GluR1 phosphorylation on Ser-831 through activation of protein kinase C (PKC) and CaMKII. Interestingly, BDNF enhances expression of GluR1 and GluR2/3 subunits in cortical neurons via the Src-family protein tyrosine kinases (PTKs) (Narisawa-Saito et al., 1999). The increase in AMPA receptor levels was blocked by a Src-family-selective PTK inhibitor. Moreover, cortical cultures from Fyn-knockout mice failed to respond to BDNF, suggesting that the Src-family kinase, Fyn, plays a crucial role in modulating AMPA receptor expression. Recently, it has been revealed that chronic BDNF application increases levels of NR2A, NR2B, and GluR1 through the MAPK/ERK pathway in developing hippocampal cultures (Kumamaru et al., 2008). BDNF increases the channel opening probability of the NMDA receptor. Whole-cell and single-channel recordings from cultured hippocampal neurons reveal that BDNF augmented glutamate-evoked, but not acetylcholine-evoked, currents and increased NMDA receptor opening probability (Levine et al., 1998). Tyrosine phosphorylation of NR1 and NR2B NMDA receptor subunits by BDNF was also reported. BDNF acutely elicits an increase in phosphorylation of the NR1 in hippocampal neurons. This effect occurred in synaptoneuroosomes, which contain both pre- and postsynaptic components (Suen et al., 1997). Furthermore, postsynaptic NR2B was phosphorylated at Tyr1472 by BDNF (Alder et al., 2005). Crozier et al. (1999) reported that BDNF enhanced activity of NR2B-containing NMDA receptors in cultured hippocampal neurons. Interestingly, antagonists of PKC and PKA had no effect on the response to BDNF, whereas an antagonist of CaMKII reduced response to BDNF.

In addition to the contribution to the activity and phosphorylation of NMDA receptors, BDNF increases

the expression of NMDA receptor subunits. In cultured hippocampal neurons, BDNF up-regulates the levels of NMDA receptor subunits, including NR1, NR2A and NR2B associated with the plasma membrane (Caldeira et al., 2007b). Acute stimulation with BDNF up-regulates these protein levels by a mechanism sensitive to transcription and translation inhibitors. As shown above, the signaling involved in NMDA receptor regulation by BDNF is not as well characterized as that of AMPA receptors. Recently, it has been found that BDNF-dependent up-regulation of NR2A and NR2B in developing hippocampal neurons was blocked by MAPK/ERK inhibitor, suggesting involvement of the MAPK/ERK pathway (Kumamaru et al., 2008).

Morphological change in neurites by BDNF

Morphological changes in axons or dendrites induced by BDNF have been investigated from a variety of angles. Earlier studies captured the entire picture of these BDNF effects (Cabelli et al., 1995; Cohen-Cory and Fraser, 1995; McAllister et al., 1995), and subsequent studies described the signal mechanism and neurological roles of morphological changes. Thus, in this section, we focused on the influence of BDNF on morphological changes in neuronal axons, dendrites, and spines.

Axon morphology

One of the most notable effects of BDNF on axon morphology would be the induction of axon branching in CNS neurons. A pioneering study conducted by Cohen-Cory and Fraser revealed that injection of BDNF into the optic tectum of *Xenopus laevis* increased the branching and complexity of optic axon terminal arbors during development (Cohen-Cory and Fraser, 1995). In their system, an injection of neutralizing antibodies for BDNF reduced axon arborization and complexity. This evidence suggested that BDNF was involved in morphological changes in the axon. Infusion of BDNF into the primary visual cortex of cats induced disarrangement of ocular dominant column formation because competitive axon development was impaired (Cabelli et al., 1995). This suggests that strict regulation of BDNF expression is critical for proper formation of axon networks, leading to construction of the ocular dominant column.

Axon collateral branching is initiated by the appearance of localized filopodia, slender actin-rich protrusions. Application of NGF- or BDNF-coated beads to the axons of cultured DRG neurons resulted in the formation of axonal filopodia at sites of bead contact (Gallo and Letourneau, 1998), suggesting that both NGF and BDNF induce initiation of axon branching. The investigation of signal mechanisms involved in BDNF's effect on filopodia is less understood than that of NGF. However, given the similarity of both neurotrophins in

signal transduction, the filopodial effect of BDNF might be regulated through activation of the TrkB/PI3K pathway.

It has been widely accepted that BDNF promotes axon elongation, such as sensory and motor axons in the limb bud (Tucker et al., 2001) or hippocampal neuron (Yoshimura et al., 2005). However, some studies suggest that this may not have always been the case. Ozdinler and Macklis (2006) indicated that BDNF enhanced branching and arborization, but not axon outgrowth of corticospinal motor neurons. In the corticospinal motor neurons, IGF-1 specifically caused axon elongation. This report suggests that axonal branching, arborization, and outgrowth could be independently regulated by different growth factors in the same axon. BDNF did not always induce axon elongation. It is possible that the difference in intracellular signaling stimulated by BDNF determines the action of BDNF in axonal morphology.

In general, BDNF is believed to exert a strong ability to promote axon complexity through TrkB signaling. However, BDNF acts as an axon pruning factor via p75 signaling. In sympathetic neurons, NGF is used as a target-derived neurotrophin to mediate competitive innervations between the axon and their targets. In contrast to the BDNF action on axon morphology described above, secreted BDNF from neighboring axons of sympathetic neurons activated p75 and pruned the sympathetic neuronal axon during development (Deppmann et al., 2008; Singh et al., 2008). This evidence suggests that BDNF's effect on axon morphology is dependent on the expression levels of TrkB and/or p75 in target neurons.

In immature neurons, axons are generated from neurites (Doti et al., 1988). Since one immature neuron has several neurites, one axon should be selected and generated from immature neurites for proper development. In addition to axon branching or elongation, BDNF is also involved in this process. BDNF-induced activation of TrkB/PI3K and the subsequent Akt-GSK3 β -CRMP-2 signal directly control this process (Jiang et al., 2005; Yoshimura et al., 2005). CRMP-2 regulates microtubule assembly by binding to tubulin heterodimers, thereby enhancing axon elongation and branching. Notably, inhibition of CRMP-2 activation caused the formation of multiple axon-like neurites. Knockdown of CRMP-2 caused a marked inhibition of BDNF-induced axon specification and led to the reduction of subsequent axon outgrowth and branching.

BDNF is also a well established chemoattractive factor (Song et al., 1997). The attractive turning of growth cones is influenced by BDNF as an extracellular guidance clue, which triggers extracellular Ca²⁺ influx. In this process, stimulation of TRP channels by BDNF occurs through the activation of the TrkB/PLC γ pathway (Li et al., 2005; Wang and Poo, 2005). Interestingly, both IP₃ and DAG produced by the PLC γ pathway activate the TRP channel (reviewed by Clapham, 2003).

BDNF function and signaling

Specifically, DAG directly activates TRP family channels, whereas IP_3 activates them by triggering intracellular calcium increase. Furthermore, a recent study demonstrated another mechanism for BDNF, where it was found to stimulate membrane potential shifts toward depolarization, thus inducing the growth-cone turning direction (Nishiyama et al., 2008).

Dendrite morphology

Dendritic growth is critical for the proper development of neuronal circuits. In addition to the effect on axons, BDNF strongly influences dendritic morphology. It was discovered that the regulation of cortical dendritic growth by BDNF requires endogenous electrical activity (McAllister et al., 1996). BDNF was released from dendrites and cell bodies and acted directly on adjacent neurons to induce dendritic branching and focal dendritic growth in a distance-dependent manner (Horch and Katz, 2002). In slices of ferret visual cortex, BDNF was shown to increase the number of the apical or basal dendrites of pyramidal neurons and its branching (McAllister et al., 1995). The effect of BDNF on dendritic morphology has a laminar specificity and is distinct between apical and basal dendrite. This suggests that the BDNF-induced morphological change in the dendrite was dependent on the neuronal populations and type of dendrites. Such a morphological influence was also different between each neurotrophin, suggesting a complex mechanism underlying dendritic development. These BDNF actions are thought to act through TrkB signaling. A study using TrkB knockout mice indicated that TrkB signaling is important for regulation of dendritic branching of cortical pyramidal neurons *in vivo* (Xu et al., 2000). Interestingly, pivotal roles have been implicated for the PI3K pathway on the effects of total dendritic branch length, dendritic caliber, and the number of dendrites in cooperation with MAPK/ERK signaling (Dijkhuizen and Ghosh, 2005; Kumar et al., 2005).

Spine morphology

BDNF controls the neuronal network through the rearrangement of synaptic connections and the regulation of spine morphology directly associated with BDNF-dependent synapse modulations (reviewed by Poo, 2001). The use of a genetically-modified mouse indicate the role of BDNF on synapse number. In particular, the number of synapses was increased in BDNF transgenic mice, whereas synapses were decreased in BDNF knockout mice (Causing et al., 1997). BDNF regulates the morphologies of both glutamatergic and GABAergic synapses. Inhibitory GABAergic synapses do not appear to have a dendritic spine structure and BDNF's action on GABAergic synapses are not well understood. Npas4 (Neuronal Pas Domain Protein-4), a transcription factor, was suggested

to play a role in the development of inhibitory synapses (Lin et al., 2008). BDNF mediates a portion of the effect of Npas4 on inhibitory synapse development. In contrast to GABAergic synapses, the formation of glutamatergic synapses was associated with structural changes in dendritic spines. In recent years, BDNF-induced morphological changes in dendritic spines were thought to contribute to synaptic rearrangement in neuronal plasticity. Tyler and Pozzo-Miller (2003) investigated the effects of BDNF on spine morphology by classifying them according to categories established by Peters and colleagues (Peters and Kaiserman-Abramof, 1970). Spine morphology was classified into three groups: stubby (type-I), mushroom (type-II), and thin (type-III) types. They found that long-term BDNF treatment increased spine density in apical dendrites of CA1 pyramidal neurons. They also discovered that BDNF increased both the total spine density and the proportion of stubby spines (type-I), which are thought to promote coordinated and widespread Ca^{2+} transients in dendritic and adjacent spines (Tyler and Pozzo-Miller, 2003). In addition, they found a reduction in the proportion of thin spines (type-III), which was thought to isolate Ca^{2+} transients from the parent dendrite and other spines. These results suggest that BDNF controls calcium signaling and regulates local neuronal communication among hippocampal excitatory synapses by promoting the morphological change of spines. Short-term BDNF exposure also induced enlargement of dendritic spines in glutamatergic synapses (Tanaka et al., 2008). It was suggested that such a morphological change in neuronal spines functions as a structural tag for selective trapping of proteins that may play a role in the long-term spine-head enlargement.

BDNF-stimulated changes in spine morphology depended on the activation of TrkB and the increased level of intracellular cAMP, which was presumably induced by monoamine neurotransmitters (Ji et al., 2005). The cAMP enhanced TrkB phosphorylation induced its translocation to the spine, suggesting an involvement of cAMP in full activation of the TrkB translocation. Ji et al. described it as the "gating" effect of cAMP. Following activation of TrkB, activation of PI3K/Akt signaling seems to mainly mediate spine morphology (Kumar et al., 2005). Furthermore, translation of miRNA, miR-134, in dendrites was also involved in morphological change induced by BDNF (Schratt et al., 2006). The miR-134 negatively regulates the size of postsynaptic sites through inhibiting the translation of an mRNA encoding a protein kinase, Limk1, which controls spine development through the regulation of actin filament dynamics by inhibition of ADF (actin-depolymerizing factor)/cofilin.

In summary, BDNF largely affects the overall morphology of neurons through the activation of PI3K, though growth cone turning has been shown to depend on PLC γ signaling. Given that structures of axons, dendrites and spines are regulated via intrinsically

different mechanisms, each specific signaling paradigm would be included on the list of local biological effects elicited by BDNF. To further investigate BDNF-dependent morphological change in neurites, more local signal molecules should be unveiled.

Cholesterol metabolism by BDNF

As described above, BDNF exerts its biological effects on neuronal cells via activating several intracellular signaling cascades. Interestingly, a couple of studies indicate the effect of BDNF on neuronal metabolites. One study revealed BDNF's role in neuronal energy availability (Burkhalter et al., 2003), and another report from our laboratory suggested the important function in cholesterol metabolism. In this section, potential roles of BDNF-induced cholesterol biosynthesis and its association with neuronal function are demonstrated.

Cholesterol and presynaptic function

Cholesterol is an important membrane component, a precursor compound of steroids and other derivatives, and an intracellular signaling molecule. Since cholesterol is such an indispensable molecule, abnormal cholesterol metabolism consequently causes pathogenesis in many tissues (reviewed by Dietschy and Turely, 2001). Although large amounts of brain cholesterol are present in glial cells, biochemical studies on synaptosomes and freeze-fracture electron microscopy indicate the presence of cholesterol in presynaptic terminals (reviewed by Pfrieger, 2003). Several lines of evidence suggest that cholesterol is an essential element of the biogenesis and transport of synaptic vesicles (SV). A study that identified synaptophysin as a major cholesterol-binding protein showed that the regulatory mechanism of SV availability depended on the amount of cholesterol (Thiele et al., 2000). It is possible that the cholesterol-dependent interactions of SV proteins, including the SNARE complex, may affect the process of exocytosis at presynaptic sites. Furthermore, cholesterol was accepted as one of the major components of lipid rafts. Neuronal lipid rafts from brain tissue, as recognized by their detergent-resistant membrane fractions, are enriched by a subset of synaptic proteins (Chamberlain et al., 2001; Lang et al., 2001; Hering et al., 2003). This suggests that the molecular interaction of synaptic proteins with cholesterol might determine their localization, and that a change in cholesterol levels affects presynaptic functions.

Neurotrophin and cholesterol biosynthesis

Mauch et al. (2001) demonstrated the importance of glia-derived cholesterol in synaptic development. Cholesterol enhanced synaptic efficacy, although

cholesterol itself demonstrated no effect on synaptic number (Christopherson et al., 2005). It has been shown that a blockade of cholesterol biosynthesis affects the dendritic and axonal development in cortical and hippocampal neurons (Ko et al., 2005). Our study also indicates that cultured cortical and hippocampal neurons actively synthesize cholesterol (Suzuki et al., 2007). It was determined that BDNF enhances cholesterol biosynthesis through the activation of TrkB. Interestingly, the BDNF-mediated increase in cholesterol occurred in rafts with an increase in presynaptic proteins, suggesting the possibility that BDNF induces presynaptic development via controlling the amount of presynaptic cholesterol. Indeed, an electrophysiological experiment revealed that BDNF-dependent cholesterol biosynthesis plays a role in the maturation of a readily releasable pool of synaptic vesicles, suggesting that BDNF-dependent cholesterol biosynthesis is necessary for synapse development. In contrast, a recent study found lower levels of cholesterol biosynthesis in retinal ganglion cell (RGC) neurons compared to glial cells (Nieweg et al., 2009). They concluded that these neurons could not produce cholesterol efficiently and that they depended on an external source of lipids. This contradictory result may suggest that the action of cholesterol biosynthesis is largely dependent on varying cell types. TrkB signaling via cholesterol-rich lipid rafts is important for BDNF function, such as synaptic modulation, calcium signaling, dendritic growth, chemotropic guidance of growth cones, and endocytosis of TrkB (Guirland et al., 2004; Suzuki et al., 2004; Pereira and Chao, 2007; Takemoto-Kimura et al., 2007). However, as a recent study indicated an enhanced signaling of TrkB by cholesterol loss (Martin et al., 2008), further studies are necessary to unveil the relationship between cellular cholesterol and TrkB signaling in detail.

A p75-dependent cholesterol mechanism for biosynthesis was also reported. In a PC12 cell, Yan et al. (2005) first demonstrated that cholesterol biosynthesis plays a role in pro-apoptotic action via p75, although it was not clear whether the cholesterol biosynthesis via p75 occurred in neurons. Recent evidence supports that cholesterol biosynthetic enzymes (3-hydroxy-3-methylglutaryl-coenzyme A reductase and 7-dehydrocholesterol reductase) are co-expressed in p75-positive neurons throughout the adult murine brain (Korade et al., 2007), indicating a possibility that neurotrophin receptor interacting factor (NRIF) is involved in the p75-dependent cholesterol biosynthesis (Korade et al., 2008).

In addition to cholesterol biosynthesis, BDNF influences neuronal energy and amino acid homeostasis. During neuronal development, BDNF increases glucose utilization with the expression of neuronal glucose transporter GLUT3 (Burkhalter et al., 2003). The energy produced from glucose was used to transport extracellular amino acids into the cell to prepare the de

novo protein synthesis induced by BDNF. This energy from glucose would also be used to synthesize cholesterol.

BDNF and mental illness

As mentioned above, BDNF is a critical neurotrophin for the survival and morphogenesis of neurons, playing important roles in the maintenance and plasticity of the neural circuit. Thus, it is possible that BDNF has an additional influence on the human mind and consciousness. In fact, many reports suggest that BDNF expression is decreased in several mental disorders, including schizophrenia, bipolar disorder, and major depression (Knable et al., 2004; Gervasoni et al., 2005; Karege et al., 2005). Patients with these disorders exhibit reduced volume of various brain regions in addition to neuronal atrophy. For example, a lower volume of the hippocampus and amygdala is observed in patients with major depression (Campbell et al., 2004). A reduction of prefrontal cortex volume in schizophrenic patients is reported to be related to the genotype of the BDNF gene (Varnäs et al., 2008). The met polymorphism at codon 66 of the BDNF gene, compared with that of the Val polymorphism, decreases BDNF trafficking (Egan et al., 2003; Chen et al., 2004). In addition, the Val/Met polymorphism correlates with a lower hippocampal volume, which has been implicated in increasing susceptibility to bipolar disorder (Chepenik et al., 2009). Moreover, alterations of brain volume and BDNF genotype are associated with declined working memory and cognitive dysfunction in the disorders listed above (Ho et al., 2006; Gatt et al., 2009). Possible involvement of BDNF via antidepressant mechanisms has been investigated by using animal experiments; chronic treatment of rats with antidepressants increases mRNA levels of BDNF in the hippocampus (Martínez-Turrillas et al., 2005; Castrén et al., 2007). In cultured cortical neurons, the antidepressant, imipramine, potentiates the release of glutamate elicited by acute BDNF application (Yagasaki et al., 2006). Taking all these findings together, BDNF may play a critical role in the pathophysiology of mental disorders.

Stress and BDNF

In addition to genetic predisposition, environmental and life events are closely related to the onset of mental illness (de Kloet et al., 2005; Gatt et al., 2009). Under stressful conditions, glucocorticoid (cortisol in humans, corticosterone in rodents) levels in serum are increased via activation of the HPA-axis (Hypothalamic-Pituitary-Adrenal axis). In general, this adrenal hormone is essential for energy production to cope with stressful situations in addition to suppressing the immune system (Franchimont, 2004). Interestingly, growing evidence suggests that glucocorticoid has an effect on neuronal function. Acutely elevated or low doses of

glucocorticoid demonstrate trophic and protective effects on neurons (Gould et al., 1990). For instance, a moderate level of glucocorticoid is required for the cognitive function of rats, which is governed in the prefrontal cortex (Mizoguchi et al., 2004). Neuronal spine generation was increased by glucocorticoid treatment given within an hour in CA1 pyramidal neurons of rat hippocampal slice cultures, suggesting that acute glucocorticoid increases synaptic plasticity (Komatsuzaki et al., 2005). Enhanced excitability of the hippocampal-amygdala system by glucocorticoid is suggested to be important for consolidating the memory of adverse experiences and arousing situations (de Kloet et al., 2005). However, when excessive stress is prolonged, the stress hormone level is no longer under tight control by the HPA-axis. In normal individuals, the activation of the HPA-axis is terminated within a few hours by the negative feedback effect of glucocorticoid. The lost regulation of the HPA-axis may result in the sustained elevation of glucocorticoid, and this abnormally elevated hormone may then damage CNS neurons as well as the HPA-axis (Watanabe et al., 1992; McEwen, 2005). Indeed, abnormally prolonged activation of the HPA-axis is observed in depressive patients (Kunugi et al., 2006). How does the BDNF level respond to such stressful conditions? Many reports show a significant decrease of BDNF in the brains of animals under stress (Schaaf et al., 2000; Duman and Monteggia, 2006). Glucocorticoid administration also decreases BDNF expression in the hippocampus (Hansson et al., 2003; Smith et al., 1995). Therefore, the stress-induced reduction in BDNF expression may be a part of the pathophysiology of mental disorders. However, the involvement of glucocorticoids in BDNF-activated signaling pathways needs to be studied further.

Stress hormones interfere in BDNF-stimulated intracellular signaling

We recently examined the effect of dexamethasone exposure (DEX, a synthetic glucocorticoid, selective ligand for glucocorticoid receptor, GR) on immature cultured hippocampal neurons (Kumamaru et al., 2008). The hippocampus is a critical region for regulating HPA-axis activity. As we previously reported, DEX pretreatment inhibits the BDNF-dependent dendrite outgrowth in developing neurons (Fig. 1A). Accordingly, BDNF-enriched synaptic proteins, including NR2A (Fig. 1B), NR2B, GluR1, and synapsin I (Fig. 1B), were suppressed by DEX, and the inhibitory action of DEX influenced neuronal function even after the neurons had matured (Kumamaru et al., 2008). The inhibitory action of DEX on the BDNF effect may occur via inhibition of the BDNF-activated MAPK/ERK1/2 pathway (Fig. 1C), which is an important pathway for synaptic maturation and dendritic outgrowth (Numakawa et al., 2004; Matsumoto et al., 2006; Kumamaru et al., 2008). The negative effect of DEX on

the MAPK/ERK1/2 pathway was reported in the analysis of another growth factor - PDGF. PDGF (platelet-derived growth factor) induced the activation of MAPK/ERK1/2, while pretreatment with DEX inhibited such PDGF effects (Obradovic et al., 2006). Reduced activation of ERK1/2 was observed in the hippocampus of mice after they were chronically administered corticosterone *in vivo* (Gourley et al., 2008). In contrast, it is also reported that stress acutely activates the MAPK/ERK1/2 pathway (Yang et al., 2004). It is possible that cells, including neurons, have negative feedback systems in place to stop the activated signaling within a certain time-frame. Sustained elevation of glucocorticoid may exhaust the ERK1/2 activation by affecting any number of unknown phosphatases. Recent evidence demonstrates that many phosphatases participate in the dephosphorylation of the phosphorylated-ERK1/2 (Keyse, 2000). Indeed, it is reported that glucocorticoid induces the expression of MAPK phosphatase-1 (MKP-1), resulting in a decrease in the phosphorylation of MAPK/ERK1/2 in the mast cell line (Kassel et al., 2001).

Long-lasting changes of neural function caused by glucocorticoids may be involved in the pathophysiology of mental disorders caused by early life stress as reviewed by Cirulli et al., (2009). Prenatal and neonatal

rats that received glucocorticoid treatment exhibited an increased brain ventricular volume in addition to decreased spatial memory (Kamphuis et al., 2003; He et al., 2004). The infants of rats repeatedly separated from their mothers demonstrated decreased neurogenesis in the hippocampus, reduced working memory, and exhibited anxiety-like behavior after maturing (Huot et al., 2002; Mirescu et al., 2004). Maternal-separation is also suggested to influence the development of the HPA-axis (Liu et al., 1997). Epigenetic modulation of GR expression is suggested to be involved in the maturation of the HPA-axis (Weaver et al., 2004). In frequently nursed rat infants, GR expression was increased in the hippocampus via reducing the methylation of the promoter region of the glucocorticoid receptor gene. In contrast, GR expression was kept at a low level in 'rarely handled' infants, resulting in elevated activity of the HPA-axis, lowered synaptogenesis in the hippocampus, and poor spatial memory after reaching adulthood (Liu et al. 2000). These findings suggest that an adequate level of GR expression in the CNS is needed for normal regulation of the HPA-axis. Maternal separation during the neonatal period was shown to influence BDNF expression levels in the hippocampus after maturation (Roceri et al., 2002; Cirulli et al., 2009). Prevention of trophic signaling of BDNF during




Fig. 1. Glucocorticoid inhibits the BDNF-up-regulated synaptic proteins via suppressing the activation of MAPK/ERK pathway. **A.** Cultured hippocampal neurons at 4 days *in vitro* (DIV4) were double-stained by anti-MAP2 (Green, microtubule-associated protein 2, neuronal dendritic marker), and anti-glutamate (Red, glutamatergic neuron marker) antibodies. BDNF increased the number of neurites of glutamatergic neuron, but it was inhibited by pretreatment with DEX (DEX, a synthetic glucocorticoid, 10 μ M). DEX was applied at DIV1, and BDNF (100 ng/ml) was applied at DIV2 in the presence or absence of DEX. **B.** BDNF-increased synapsin I (presynaptic) and NR2A (postsynaptic) proteins was

inhibited by DEX. Expression of TUJ1 (class III β -tubulin), a neuronal marker, was not changed. **C.** pERK1/2 (phosphorylated ERK1/2) and total ERK1/2 at 6 hours after BDNF application with or without DEX pretreatment. BDNF-stimulated ERK1/2 activation was decreased by DEX.

BDNF function and signaling

development may decrease neuronal network activity after neurons mature, which may lead to a decrease in the activity-dependent production and release of BDNF. BDNF mRNA expression, containing exon II and IV of the hippocampus and prefrontal cortex, was decreased in adult rats administered chronic corticosterone (Dwivedi et al., 2006). However, an increase of BDNF expression in chronically separated infants was reported (Nair et al., 2007). Duration and potency of the stress may regulate the expression level of splice variants for BDNF mRNA in each brain region (Nair et al., 2007; Cirulli et al., 2009).

Correlation between BDNF function and steroid-hormonal action

Another steroid hormone, estrogen, is well known for its relation to BDNF function. A number of reports suggest that estrogen increases BDNF expression (reviewed by Sohrabji and Lewis, 2006). Moreover, estrogen and BDNF may share common signaling pathways, including MAPK/ERK1/2, PI3K, and PLC γ pathways, as both factors have a similar impact on neuronal cells, including facilitation of neuronal plasticity and neuroprotection (Scharfman and MacLusky, 2006). Thus, there is a possibility that both BDNF and estrogen enhance these signaling pathways cooperatively. In contrast to estrogen, glucocorticoid may have a negative influence on BDNF function by inhibiting the BDNF/TrkB signaling. Recently, we have found that chronic exposure to DEX suppresses BDNF-induced glutamate release via weakening the activation of PLC γ /Ca²⁺ signaling in cultured cortical neurons (Numakawa et al., 2009). The GR interacts with TrkB, and the TrkB-GR interaction was reduced due to the decline in GR expression following DEX treatment. In our system, BDNF-dependent binding of PLC γ to TrkB was diminished by DEX. SiRNA transfection for a decrease in endogenous GR mimicked the inhibitory action of DEX. Conversely, the DEX-inhibited PLC γ signaling was recovered by GR overexpression. Another group also showed an essential interaction of GR to a receptor for transducing the cytosolic signal in a T-cell receptor on immune T-cells (Lowenberg et al., 2007). Similarly another receptor kinase, FMS-like tyrosine kinase 3, was also found to interact with GR (Asadi et al., 2008). GR was detectable in the lipid raft on the plasma membrane (Jain et al., 2005; Matthews et al., 2008), therefore, GR may take part in the various signal transductions via regulation of activity of membrane receptors.

Interestingly, acute glucocorticoid exposure induces the phosphorylation of TrkB and promotes neuronal survival (Jeanneteau et al., 2008). The phosphorylation of TrkB peaks at 5 hours and gradually decreases after glucocorticoid exposure. Indeed, activation of TrkB, PLC γ , Akt, and ERK has been shown to increase by short-term application of glucocorticoid, reaching the

maximum level at 2–4 h after the application in our cortical cultures. However, GR expression level was not altered by such a short glucocorticoid exposure (Numakawa et al., 2009). Jeanneteau et al. (2008) suggests that the activation of TrkB is achieved through regulation of unknown genes, as TrkB was not activated with a mutant GR that lacks the DNA binding domain. Taken together GR may have two 'faces'; the first as a transcription factor and the second as an adaptor molecule of a membrane receptor, such as TrkB. Because long-lasting exposure of glucocorticoid alters the expression level of its receptor, GR, the duration of glucocorticoid exposure may be important when interpreting the interaction between glucocorticoid/GR action and BDNF/TrkB signaling.

Regulation of BDNF expression

BDNF is broadly expressed in the developing and adult mammalian brain, being especially abundant in the hippocampus, cerebral cortex, cerebellum and amygdala. Expression levels of BDNF are dramatically increased during the first few weeks of postnatal development in rodents (Ernfors et al., 1990; Hofer et al., 1990; Conner et al., 1997; Yan et al., 1997). Intracellular BDNF expression is found predominantly in glutamatergic neurons, not in interneurons or astrocytes, under physiological conditions (although its expression can be detected in cultured astrocytes) (Zafra et al., 1992; Yoshimoto et al., 1995; Cellerino et al., 1996; Rocamora et al., 1996; Gorba and Wahle, 1999). The BDNF gene is comprised of at least eight promoters, each of which initiate transcription of alternative 5' exon spliced onto a common 3' exon, encoding the entire open reading frame of the BDNF protein. Additionally, BDNF mRNA has two distinct polyadenylation sites resulting in production of distinct populations of mRNA, with either short or long 3' untranslated regions (3' UTRs). At least 18 distinct transcripts are generated through the complexity of the BDNF gene (Liu et al., 2006; Aid et al., 2007). Possible explanations for the presence of multiple mRNA variants generating the same protein are: different sequences of mRNA show different distributions and/or translational efficacies, and different transcript expressions are regulated by different stimuli. Indeed, dendritic targeting of BDNF mRNA stimulated by neuronal activity has been reported (Tongiorgi et al., 1997; Tongiorgi, 2008). An et al., recently demonstrated that BDNF mRNA with long 3' UTR is selectively transported to dendrites of hippocampal neurons, and BDNF translated from this transcript is required for spine morphology and synaptic plasticity in dendrites (An et al., 2008).

Neuronal activity regulates the transcription of a large set of genes, many of which encode proteins that modify synaptic function and activity-dependent adaptation to neuronal responses that are believed to be critical for the refinement of neuronal connections

during development and for mature brain functioning. As expected, expression of BDNF in neurons is correlated with neuronal activity. BDNF mRNA level is rapidly increased by seizure activity in the hippocampus and the cerebral cortex (Castrén et al., 1989; Ernfors et al., 1991). Down-regulation of BDNF mRNA was observed in the visual cortex of dark-reared rats by blockade of visual input (Castrén et al., 1992). In cultured neurons, depolarization induced by glutamate or high concentrations of potassium increased the levels of BDNF mRNA, while a blockade of neuronal activity with γ -aminobutyric acid (GABA) decreased such levels (Lindholm et al., 1994; Berninger et al., 1995). It has also been shown that BDNF expression is regulated by intracellular Ca^{2+} and CREB, a key transcription factor that mediates stimulus-dependent transcription (Shieh et al., 1998; Tao et al., 1998). Greenberg and colleagues have demonstrated the importance of the activity-dependent component of BDNF gene transcription for inhibitory synapse development. They introduced a subtle mutation into the mouse BDNF gene that blocks the ability of CREB to bind BDNF promoter IV. These mice demonstrate impairments of the sensory experience-dependent induction of BDNF expression and fewer inhibitory synapses in the cortex (Hong et al., 2008). Regulation of BDNF transcription is also putatively involved in the pathophysiology and treatment of psychiatric disorders. Recent studies have shown that methylation in a BDNF promoter region affects the regulation of BDNF expression. DNA methylation regulates mRNA expression and typically occurs on cytosine residues in which the cytosine is followed by a guanine residue (CpGs) in vertebrates. Methyl-CpG-binding protein 2 (MeCP2) is a member of the methyl-CpG-binding protein family that functions as a transcriptional regulator. Mutations in MeCP2 were found in many cases of Rett syndrome, an X-linked disorder characterized by arrested neurological development and subsequent cognitive and motor dysfunction. Originally, MeCP2 was characterized as a transcriptional repressor for many genes including BDNF. Indeed, MeCP2 binds to a BDNF promoter and represses expression of BDNF mRNA in cultured neurons (Chen et al., 2003). However, BDNF was down-regulated both at the mRNA and protein levels in MeCP2-null mice (Chang et al., 2006). The more recent study of Chahrour et al. suggests a potential explanation for the MeCP2 function by demonstrating the interaction between MeCP2 and CREB (Chahrour et al., 2008). Using chromatin immunoprecipitation, they verified the association of MeCP2 with CREB at a few target genes in the hypothalamus. Interestingly, MeCP2 functions as both an activator and a repressor, depending on whether it is associated with CREB or not, respectively. Their finding may settle irreconcilable data on the relationship between MeCP2 and BDNF transcription and provide future therapeutic strategies for Rett syndrome. In addition, social defeat stress resulted in a sustained

suppression of BDNF transcription through histone methylation, whereas chronic (but not acute) imipramine treatment was shown to restore BDNF synthesis through histone acetylation (Tsankova et al., 2006). Lithium and valproic acid (VPA), two primary drugs used to treat bipolar mood disorder, selectively increased the levels of exon IV containing BDNF mRNA, as well as the activity of BDNF promoter IV. Lithium and VPA affect the BDNF promoter through inhibition of glycogen synthase kinase-3 (GSK-3) and histone deacetylase (HDAC), respectively (Fukumoto et al., 2001; Yasuda et al., 2009).

Mechanisms of BDNF secretion

BDNF is translated at the rough endoplasmic reticulum (ER) as a precursor protein (proBDNF: 32 kDa) which is subsequently cleaved proteolytically to produce the mature form of BDNF (13 kDa). Synthesized proBDNF is moved to the Golgi apparatus and accumulated in membrane stacks of the trans-Golgi network (TGN). Finally, BDNF-containing vesicles bud off from the TGN and are then transported to the secretion sites. Depending on whether the secretion occurs spontaneously or in response to neuronal activity, neurotrophin secretion is classified into "constitutive" or "regulated" pathways, respectively. BDNF appears to be sorted primarily into the regulated pathway in hippocampal neurons (Goodman et al., 1996; Farhadi et al., 2000; Mowla et al., 2001). In the regulated pathway, transport of BDNF-containing vesicles to either axon terminals or dendrites along microtubules has been reported (Kohara et al., 2001; Kojima et al., 2001; Gartner and Staiger, 2002; Adachi et al., 2005), although the specific sites for BDNF secretion have not been elucidated.

Recent studies have revealed some of the details of BDNF vesicular sorting. The pro-region of BDNF has been implicated as a regulator of BDNF sorting to secretory vesicles. A single nucleotide polymorphism (SNP) was identified at amino acid 66 (Val66Met) in the sequence encoding the pro-region of BDNF. Egan and colleagues reported that the met allele was associated with decreased episodic memory and abnormal hippocampal activation in humans. Interestingly, met-BDNF-GFP in cultured hippocampal neurons failed to localize to secretory granules for transport to synapses. Lower secretion of met-BDNF-GFP compared with met type was due to the impairment of BDNF sorting (Egan et al., 2003). NT-4, which is rarely sorted into secretory vesicles, was redirected to sort into secretory vesicles by fusing to the pro-region of BDNF (Brigadski et al., 2005). However, the pro-region of BDNF alone fused to GFP was not sufficient to induce sorting. This data suggests that the pro-region of BDNF contains important determinants for vesicular targeting, although additional targeting sequences in the mature region of BDNF are also required. Furthermore, binding of BDNF to lipid-

BDNF function and signaling

raft-associated sorting receptor carboxypeptidase E (CPE) in the TGN appears to be important for sorting (Lou et al., 2005). CPE knockout mice demonstrate a lack of BDNF secretion through the regulated pathway. Interestingly, sortilin, a trans-membrane protein, has also been implicated in the sorting of proBDNF to secretory granules (Chen et al., 2005). Sortilin is distributed on the membrane of secretory granules and interacts specifically with the pro-region of proBDNF. Interestingly, a truncated form of sortilin was not able to sort proBDNF into the secretory vesicles. The involvement of Ca²⁺-dependent activator protein for secretion 2 (CAPS2) for BDNF secretion was also reported. CAPS2, a secretory granule-associated protein, is abundant at the parallel fiber terminals of granule cells in the cerebellum. CAPS2 knock-out mice demonstrate autistic-like behavioral phenotypes in addition to deficient release of BDNF and NT-3 (Sadakata et al., 2007). Importantly, the human CAPS2 gene is located on chromosome 7q31.32, within a critical autism susceptibility locus 1.

It is still controversial as to where and how pro-neurotrophins are processed into mature neurotrophins in the CNS. Originally, it had been thought that pro-neurotrophins are prototypically cleaved by furin and pro-protein convertases (PCs) in the TGN or in secretory granules before secretion (Seidah et al., 1996; Matsumoto et al., 2008). However, recent studies have indicated that a considerable amount of BDNF is secreted in the pro-form from neurons. Released proBDNF is subsequently processed to mature BDNF extracellularly by proteases such as plasmin or matrix metalloproteinases (Pang et al., 2004; reviewed by Lu et al., 2005; Yang et al., 2009). A possible link between Huntington's disease (HD) and BDNF functions has also been reported. HD is an autosomal dominant neurodegenerative disease characterized by relatively selective degeneration of striatal neurons which leads to psychiatric, cognitive and motor dysfunction. Polyglutamine expansion (polyQ) in the protein huntingtin (htt) is thought to be the principal mechanism for neuronal toxicity in HD. Interestingly, wild-type htt appears to play two roles: One as a transcription factor to facilitate expression of BDNF (reviewed by Zuccato and Cattaneo, 2007) and the other as a regulator of BDNF-containing vesicle transport. Mutant (PolyQ)-htt perturbs post-Golgi trafficking of BDNF in the regulated secretory pathway, while wild-type htt enhances trafficking (Gauthier et al., 2004; del Toro et al., 2006). Further, axonal transport of BDNF-containing vesicles is disrupted in cultured striatal and hippocampal neurons but not in cortical neurons (Her and Goldstein, 2008). These findings suggest that mutation of htt reduces levels of BDNF in the striatum by inhibiting gene expression and perturbing axonal transport of BDNF-containing vesicles to the striatum. Molecular mechanisms of BDNF secretion have been uncovered by an elegant series of studies by Lessmann and colleagues.

The activity-dependent postsynaptic secretion of BDNF critically depends on intracellular Ca²⁺ concentration. The Ca²⁺ increase is through ionotropic glutamate receptors, voltage-gated Ca²⁺ channels (VDCC), and the internal Ca²⁺ stores. Furthermore, activation of CaMKII and PKA contribute to BDNF secretion, although Trk signaling and activation of Na⁺ channels are not required (Hartmann et al., 2001; reviewed by Lessmann et al., 2003; Kolarow et al., 2007). Recent reports suggest that the Golgi apparatus is distributed in dendritic shafts as well as the cell soma, and has even been identified as a local BDNF secretory pathway in dendrites (Horton and Ehlers, 2003; Horton et al., 2005). Taking into consideration the possibility of the local translation of BDNF in dendrites and spines (Zhang and Poo, 2002; Tanaka et al., 2008), further studies need to reveal the complex and dynamic secretory systems of BDNF.

The fate of secreted BDNF

BDNF causes many cellular responses after binding to and activating TrkB. Mainly, two possible mechanisms occur in order to facilitate intracellular signal transduction after TrkB activation (reviewed by Nagappan and Lu, 2005; reviewed by Ibáñez, 2007). The first involves internalization of BDNF-bound TrkB followed by axonal transport of "signaling endosomes." The second involves lateral movement of TrkB from the extrasynaptic membrane to lipid rafts to create a "signaling platform," as mentioned above in this review. The "signaling endosomes" are involved in BDNF-induced survival and morphological change, which require a de novo transcriptional reaction. Long-range travel of "signaling endosomes" from the distal neurites (where BDNF acts) to the cell body is essential for this type of BDNF-dependent biological action. Endocytosis of and retrograde transport of ligand/Trk complexes induces the activation of downstream signaling, including the MAPK/ERK1/2, PI3K and PLC γ pathways (reviewed by Yano and Chao, 2004; reviewed by Lu, 2003; reviewed by Zweifel et al., 2005; reviewed by Bronfman et al., 2007). Several lines of experiments concerning NGF signaling indicate that the signaling endosomes are generated in a clathrin-dependent manner (Grimes et al., 1996; Howe et al., 2001), or require pincher-mediated endocytosis (Shao et al., 2002; Valdez et al., 2007). Dynein motor complex- and microtubule-dependent transport are also thought to be responsible for the Trk-mediated retrograde signals. A recent study indicates that IC-1B, a neuron-specific isoform of the intermediate chain (IC) of dynein, preferentially binds to and transports the TrkB signaling endosomes, while the ubiquitously expressed IC-2C isoform does not (Ha et al., 2008). Furthermore, a requirement of axonal ERK5 and PI3K activation as the retrograde survival signal has been reported (Kuruvilla et al., 2000; Watson et al., 2001). Surprisingly, in cultured dorsal root ganglion (DRG) neurons, newly synthesized CREB in the axons

stimulated by NGF travels via retrograde transport with appropriate signaling endosomes and is required for NGF-dependent retrograde survival (Cox et al., 2008). Activated CREB was co-localized with pTrkA and pERK5, suggesting the involvement of CREB and ERK5 in the TrkA signaling endosome. This data indicates that these downstream signaling molecules participate in the Trks signaling endosomes (reviewed by Cosker et al., 2008). A p75-dependent signal is also generated through the retrograde-transported endosomes in sensory neurons (Curtis et al., 1995; Deinhardt et al., 2006). Some studies show that p75 is cleaved in a ligand-dependent manner, and the resulting intracellular fragment induces intracellular signaling (Kanning et al., 2003; Kenchappa et al., 2006). As there are a number of interacting factors, p75 may undergo different processing and have different signaling mechanisms depending on the type of stimulus or cell it is involved with. Recent studies have shed light on a new aspect of the fate of secreted BDNF: "recycling." Canossa and colleagues have shown that exogenously applied BDNF was internalized by hippocampal neurons via a TrkB-dependent mechanism and rapidly becomes available for activity-dependent secretion. The recycled BDNF played the same role as newly synthesized BDNF in mediating the late-phase LTP (Santi et al., 2006). Interestingly, newly synthesized BDNF in neurons after theta-burst stimulation (TBS) is secreted in proBDNF form and is then rapidly internalized by astrocytes in cortical slices via the formation of a complex with p75 and subsequent clathrin-dependent endocytosis. The endocytosed proBDNF is resecreted via a SNARE-dependent mechanism in astrocytes (Bergami et al., 2008).

Concluding remarks

BDNF plays a critical role in determining the fate of various CNS neurons. BDNF induces many neuronal responses through activation of TrkB, or other receptors such as p75. In general, BDNF maintains dual roles: Firstly, BDNF promotes positive effects in the brain, including promotion of neuronal survival, maintenance of LTP, etc. via TrkB receptors. Secondly, and conversely, BDNF generates negative effects through its induction of apoptosis, depression of neuronal plasticity, etc. via p75 receptors. Recent high-impact discoveries have been made: Lessmann and colleagues have illustrated the activity-dependent secretion of neurotrophins (Hartmann et al., 2001; Lessmann et al., 2003), while Nagappan et al. have discovered that both proBDNF and mature BDNF are indeed secreted from neurons (Nagappan et al., 2009; Yang et al., 2009). It has also been found that high affinity interactions of pro-neurotrophins with p75 have contributed to apoptosis via p75 activation (Lee et al., 2001). Remarkably, roles of BDNF have been implicated in the pathophysiology of various brain diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease (reviewed

by Mattson 2008). In addition, it is possible that BDNF is involved in several psychiatric disorders, including schizophrenia, bipolar disorder, and major depression (Knable et al., 2004; Gervasoni et al., 2005; Karege et al., 2005). There are many different ways that BDNF acts - constitutive vs. regulated secretion, dendritic vs. axonal secretion sites, pro- vs. mature forms, autocrine vs. paracrine secretion (Acheson et al., 1995; Marini et al., 1998), and TrkB vs. p75 receptors. Furthermore, there are several signaling pathways stimulated by BDNF, depending on the molecular and cellular context. In the future, precise understanding of intracellular and extracellular actions of BDNF will further elucidate biological systems and, more importantly, will help develop new therapeutic targets for psychiatric and neurodegenerative diseases.

Acknowledgments. We thank Regeneron Pharmaceutical Co., Takeda Chemical Industries, Ltd., and Sumitomo Co. Ltd. for donating the BDNF. This study was supported by a grant from the Ichiro Kanehara Foundation (T. N.), the Japan Health Sciences Foundation (Research on Health Sciences focusing on Drug Innovation) (H. K.), Health and Labor Sciences Research Grants (Research on Psychiatric and Neurological Diseases and Mental Health) (H. K.), the Mitsubishi Pharma Research Foundation (H. K.), a grant from the Japan Foundation for Neuroscience and Mental Health (H. K.), the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO) (H. K.), Program for Improvement of Research Environment for Young Researchers from Special Coordination Funds for Promoting Science and Technology (SCF) commissioned by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (S. S.), and Grant-in-Aid for Young Scientists (A) (21680034) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (T. N.).

References

- Acheson A., Conover J.C., Fandl J.P., DeChiara T.M., Russell M., Thadani A., Squinto S.P., Yancopoulos G.D. and Lindsay R.M. (1995). A BDNF autocrine loop in adult sensory neurons prevents cell death. *Nature* 374, 450-453.
- Adachi N., Kohara K. and Tsumoto T. (2005). Difference in trafficking of brain-derived neurotrophic factor between axons and dendrites of cortical neurons, revealed by live-cell imaging. *BMC Neurosci.* 6, 42.
- Aid T., Kazantseva A., Piiroso M., Palm K. and Timmusk T. (2007). Mouse and rat BDNF gene structure and expression revisited. *J. Neurosci. Res.* 85, 525-535.
- Alder J., Thakker-Varia S., Crozier R.A., Shaheen A., Plummer M.R. and Black I.B. (2005). Early presynaptic and late postsynaptic components contribute independently to brain-derived neurotrophic factor-induced synaptic plasticity. *J. Neurosci.* 25, 3080-3085.
- Almeida R.D., Manadas B.J., Melo C.V., Gomes J.R., Mendes C.S., Grãos M.M., Carvalho R.F., Carvalho A.P. and Duarte C.B. (2005). Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. *Cell Death Differ.* 12, 1329-1343.
- Aloyz R.S., Bamji S.X., Pozniak C.D., Toma J.G., Atwal J., Kaplan D.R.

BDNF function and signaling

- and Miller F.D. (1998). p53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors. *J. Cell Biol.* 143, 1691-1703.
- An J.J., Gharami K., Liao G.Y., Woo N.H., Lau A.G., Vanevski F., Torre E.R., Jones K.R., Feng Y., Lu B. and Xu B. (2008). Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. *Cell* 134, 175-187.
- Asadi A., Hedman E., Widén C., Zilliacus J., Gustafsson J.A. and Wikström A.C. (2008). FMS-like tyrosine kinase 3 interacts with the glucocorticoid receptor complex and affects glucocorticoid dependent signaling. *Biochem. Biophys. Res. Commun.* 368, 569-574.
- Balkowiec A. and Katz D.M. (2002). Cellular mechanisms regulating activity-dependent release of native brain-derived neurotrophic factor from hippocampal neurons. *J. Neurosci.* 22, 10399-10407.
- Bamji S.X., Majdan M., Pozniak C.D., Belliveau D.J., Aloyz R., Kohn J., Causing C.G. and Miller F.D. (1998). The p75 neurotrophin receptor mediates neuronal apoptosis and is essential for naturally occurring sympathetic neuron death. *J. Cell Biol.* 140, 911-923.
- Barker P.A. and Shooter E.M. (1994). Disruption of NGF binding to the low affinity neurotrophin receptor p75LNTFR reduces NGF binding to TrkA on PC12 cells. *Neuron* 13, 203-215.
- Beattie E.C., Carroll R.C., Yu X., Morishita W., Yasuda H., von Zastrow M. and Malenka R.C. (2000). Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. *Nat. Neurosci.* 3, 1291-1300.
- Benmansour S., Deltheil T., Piotrowski J., Nicolas L., Reperant C., Gardier A.M., Frazer A. and David D.J. (2008). Influence of brain-derived neurotrophic factor (BDNF) on serotonin neurotransmission in the hippocampus of adult rodents. *Eur. J. Pharmacol.* 587, 90-98.
- Bergami M., Santi S., Formaggio E., Cagnoli C., Verderio C., Blum R., Berninger B., Matteoli M. and Canossa M. (2008). Uptake and recycling of pro-BDNF for transmitter-induced secretion by cortical astrocytes. *J. Cell Biol.* 183, 213-221.
- Berninger B., Marty S., Zafra F., Berzaghi M.P. and Thoenen H. (1995). GABAergic stimulation switches from enhancing to repressing BDNF expression in rat hippocampal neurons during maturation in vitro. *Development* 121, 2327-2335.
- Berninger B. and Poo M. (1996). Fast actions of neurotrophic factors. *Curr. Opin. Neurobiol.* 6, 324-330.
- Boutillier J., Ceni C., Pagdala P.C., Forgie A., Neet K.E. and Barker P.A. (2008). Proneurotrophins require endocytosis and intracellular proteolysis to induce TrkA activation. *J. Biol. Chem.* 283, 12709-12716.
- Brigadski T., Hartmann M. and Lessmann V. (2005). Differential vesicular targeting and time course of synaptic secretion of the mammalian neurotrophins. *J. Neurosci.* 25, 7601-7614.
- Bronfman F.C., Escudero C.A., Weis J. and Kruttgen A. (2007). Endosomal transport of neurotrophins: roles in signaling and neurodegenerative diseases. *Dev. Neurobiol.* 67, 1183-1203.
- Brunet A., Datta S.R. and Greenberg M.E. (2001). Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. *Curr. Opin. Neurobiol.* 11, 297-305.
- Burkhalter J., Flumelli H., Allaman I., Chatton J.Y. and Martin J.L. (2003). Brain-derived neurotrophic factor stimulates energy metabolism in developing cortical neurons. *J. Neurosci.* 23, 8212-8220.
- Cabelli R.J., Hohn A. and Shatz C.J. (1995). Inhibition of ocular dominance column formation by infusion of NT-4/5 or BDNF. *Science* 267, 1662-1666.
- Caldeira M.V., Melo C.V., Pereira D.B., Carvalho R., Correia S.S., Backos D.S., Carvalho A.L., Esteban J.A. and Duarte C.B. (2007a). Brain-derived neurotrophic factor regulates the expression and synaptic delivery of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits in hippocampal neurons. *J. Biol. Chem.* 282, 12619-12628.
- Caldeira M.V., Melo C.V., Pereira D.B., Carvalho R.F., Carvalho A.L. and Duarte C.B. (2007b). BDNF regulates the expression and traffic of NMDA receptors in cultured hippocampal neurons. *Mol. Cell. Neurosci.* 35, 208-219.
- Campbell S., Marriott M., Nahmias C. and MacQueen G.M. (2004). Lower hippocampal volume in patients suffering from depression: a meta-analysis. *Am. J. Psychiatry* 161, 598-607.
- Carroll R.C., Lissin D.V., von Zastrow M., Nicoll R.A. and Malenka R.C. (1999). Rapid redistribution of glutamate receptors contributes to long-term depression in hippocampal cultures. *Nat. Neurosci.* 2, 454-460.
- Carter B.D., Kaltschmidt C., Kaltschmidt B., Offenhäuser N., Böhm-Matthaei R., Baeuerle P.A. and Barde Y.A. (1996). Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. *Science* 272, 542-545.
- Carvalho A.L., Caldeira M.V., Santos S.D. and Duarte C.B. (2008). Role of the brain-derived neurotrophic factor at glutamatergic synapses. *Br. J. Pharmacol.* 153, S310-S324.
- Casaccia-Bonnel P., Carter B.D., Dobrowsky R.T. and Chao M.V. (1996). Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. *Nature* 383, 716-719.
- Castrén E., Zafra F., Thoenen H., Lindholm D., Gail C.M. and Isackson P.J. (1989). Limbic seizures increase neuronal production of messenger RNA for nerve growth factor. *Science* 245, 758-761.
- Castrén E., Zafra F., Thoenen H. and Lindholm D. (1992). Light regulates expression of brain-derived neurotrophic factor mRNA in rat visual cortex. *Proc. Natl. Acad. Sci. USA* 89, 9444-9448.
- Castrén E., Völkar V. and Rantamäki T. (2007). Role of neurotrophic factors in depression. *Curr. Opin. Pharmacol.* 7, 18-21.
- Causing C.G., Gloster A., Aloyz R., Bamji S.X., Chang E., Fawcett J., Kuchel G. and Miller F.D. (1997). Synaptic innervation density is regulated by neuron-derived BDNF. *Neuron* 18, 257-267.
- Cellerino A., Maffei L. and Domenici L. (1996). The distribution of brain-derived neurotrophic factor and its receptor trkB in parvalbumin-containing neurons of the rat visual cortex. *Eur. J. Neurosci.* 8, 1190-1197.
- Chahrouh M., Jung S.Y., Shaw C, Zhou X., Wong S.T., Qin J. and Zoghbi H.Y. (2008). MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science* 320, 1224-1229.
- Chamberlain L.H., Burgoyne R.D. and Gould G.W. (2001). SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. *Proc. Natl. Acad. Sci. USA* 98, 5619-5624.
- Chang Q., Khare G., Dani V., Nelson S. and Jaenisch R. (2006). The disease progression of *Mecp2* mutant mice is affected by the level of BDNF expression. *Neuron* 49, 341-348.
- Chao M.V. (1994). The p75 neurotrophin receptor. *J. Neurobiol.* 25, 1373-1385.
- Chen M.J., Nguyen T.V., Pike C.J. and Russo-Neustadt A.A. (2007). Norepinephrine induces BDNF and activates the PI-3K and MAPK cascades in embryonic hippocampal neurons. *Cell. Signal.* 19, 114-

- 128.
- Chen W.G., Chang Q., Lin Y., Meissner A., West A.E., Griffith E.C., Jaenisch R. and Greenberg M.E. (2003). Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. *Science* 302, 885-889.
- Chen Z.Y., Patel P.D., Sant G., Meng C.X., Teng K.K., Hempstead B.L. and Lee F.S. (2004). Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. *J. Neurosci.* 24, 4401-4411.
- Chen Z.Y., Ieraci A., Teng H., Dall H., Meng C.X., Herrera D.G., Nykjaer A., Hempstead B.L. and Lee F.S. (2005). Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway. *J. Neurosci.* 25, 6156-6166.
- Chepenik L.G., Fredericks C., Papademetris X., Spencer L., Lacadie C., Wang F., Pittman B., Duncan J.S., Staib L.H., Duman R.S., Gelernter J. and Blumberg H.P. (2009). Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder. *Neuropsychopharmacology* 34, 944-951.
- Christopherson K.S., Ullian E.M., Stokes C.C., Mullen C.E., Hell J.W., Agah A., Lawler J., Mosher D.F., Bornstein P. and Barres B.A. (2005). Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. *Cell* 120, 421-433.
- Cirulli F., Francia N., Berry A., Aloe L., Allegra E. and Suomi S.J. (2009). Early life stress as a risk factor for mental health: Role of neurotrophins from rodents to non-human primates. *Neurosci. Biobehav. Rev.* 33, 573-585.
- Clapham D.E. (2003). TRP channels as cellular sensors. *Nature* 426, 517-524.
- Cohen-Cory S. and Fraser S.E. (1995). Effects of brain-derived neurotrophic factor on optic axon branching and remodelling in vivo. *Nature* 378, 192-196.
- Conner J.M., Lauterborn J.C., Yan Q., Gall C.M. and Varon S. (1997). Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. *J. Neurosci.* 17, 2295-2313.
- Cosker K.E., Courchesne S.L. and Segal R.A. (2008). Action in the axon: generation and transport of signaling endosomes. *Curr. Opin. Neurobiol.* 18, 270-275.
- Cox L.J., Hengst U., Gurskaya N.G., Lukyanov K.A. and Jaffrey S.R. (2008). Intra-axonal translation and retrograde trafficking of CREB promotes neuronal survival. *Nat. Cell Biol.* 10, 149-159.
- Crozier R.A., Black I.B. and Plummer M.R. (1999). Blockade of NR2B-containing NMDA receptors prevents BDNF enhancement of glutamatergic transmission in hippocampal neurons. *Learn. Mem.* 6, 257-266.
- Curtis R., Adryan K.M., Stark J.L., Park J.S., Compton D.L., Weskamp G., Huber L.J., Chao M.V., Jaenisch R., Lee K.F., Lindsay R.M., Peter S. and DiStefano P.S. (1995). Differential role of the low affinity neurotrophin receptor (p75) in retrograde axonal transport of the neurotrophins. *Neuron* 14, 1201-1211.
- Davies A.M., Lee K.F. and Jaenisch R. (1993). p75-deficient trigeminal sensory neurons have an altered response to NGF but not to other neurotrophins. *Neuron* 11, 565-574.
- Deinhardt K., Salinas S., Verastegui C., Watson R., Worth D., Hanrahan S., Bucci C. and Schiavo G. (2006). Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. *Neuron* 52, 293-305.
- de Kloet E.R., Joëls M. and Holsboer F. (2005). Stress and the brain: from adaptation to disease. *Nat. Rev. Neurosci.* 6, 463-475.
- del Toro D., Canals J.M., Ginés S., Kojima M., Egea G. and Alberch J. (2006). Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. *J. Neurosci.* 26, 12748-12757.
- Deppmann C.D., Mihalas S., Sharma N., Lonze B.E., Niebur E. and Ginty D.D. (2008). A model for neuronal competition during development. *Science* 320, 369-373.
- Dietschy J.M. and Turley S.D. (2001). Cholesterol metabolism in the brain. *Curr. Opin. Lipidol.* 12, 105-112.
- Dijkhuizen P.A. and Ghosh A. (2005). BDNF regulates primary dendrite formation in cortical neurons via the PI3-kinase and MAP kinase signaling pathways. *J. Neurobiol.* 62, 278-288.
- Dobrowsky R.T., Werner M.H., Castellino A.M., Chao M.V. and Hannun Y.A. (1994). Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor. *Science* 265, 1596-1599.
- Dotti C.G., Sullivan C.A. and Banker G.A. (1988). The establishment of polarity by hippocampal neurons in culture. *J. Neurosci.* 8, 1454-1468.
- Duchemin A.M., Ren Q., Neff N.H. and Hadjiconstantinou M. (2008). GM1-induced activation of phosphatidylinositol 3-kinase: involvement of Trk receptors. *J. Neurochem.* 104, 1466-1477.
- Duman R.S. and Monteggia L.M. (2006). A neurotrophic model for stress-related mood disorders. *Biol. Psychiatry* 59, 1116-1127.
- Dwivedi Y., Rizavi H.S. and Pandey G.N. (2006). Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone. *Neuroscience* 139, 1017-1029.
- Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B. and Weinberger D.R. (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* 112, 257-269.
- Ermfors P., Wetmore C., Olson L. and Persson H. (1990). Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family. *Neuron* 5, 511-526.
- Ermfors P., Bengzon J., Kokaia Z., Persson H. and Lindvall O. (1991). Increased levels of messenger RNAs for neurotrophic factors in the brain during kindling epileptogenesis. *Neuron* 7, 165-176.
- Farhadi H.F., Mowla S.J., Petrecca K., Morris S.J., Seidah N.G. and Murphy R.A. (2000). Neurotrophin-3 sorts to the constitutive secretory pathway of hippocampal neurons and is diverted to the regulated secretory pathway by coexpression with brain-derived neurotrophic factor. *J. Neurosci.* 20, 4059-4068.
- Franchimont D. (2004). Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. *Ann. NY Acad. Sci.* 1024, 124-137.
- Franke T.F., Kaplan D.R., Cantley L.C. and Toker A. (1997). Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. *Science* 275, 665-668.
- Friedman W.J. (2000). Neurotrophins induce death of hippocampal neurons via the p75 receptor. *J. Neurosci.* 20, 6340-6346.
- Fukumoto T., Morinobu S., Okamoto Y., Kagaya A. and Yamawaki S. (2001). Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. *Psychopharmacology* 158, 100-106.

BDNF function and signaling

- Gallo G. and Letourneau P.C. (1998). Localized sources of neurotrophins initiate axon collateral sprouting. *J. Neurosci.* 18, 5403-5414.
- Gartner A. and Staiger V. (2002). Neurotrophin secretion from hippocampal neurons evoked by long-term-potential-inducing electrical stimulation patterns. *Proc. Natl. Acad. Sci. USA* 99, 6386-6391.
- Gatt J.M., Nemeroff C.B., Dobson-Stone C., Paul R.H., Bryant R.A., Schofield P.R., Gordon E., Kemp A.H. and Williams L.M. (2009). Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. *Mol. Psychiatry*. (In press).
- Gauthier L.R., Charrin B.C., Borrell-Pagès M., Dompierre J.P., Rangone H., Cordellères F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S. and Saudou F. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. *Cell* 118, 127-138.
- Gervasoni N., Aubry J.M., Bondolfi G., Osiek C., Schwald M., Bertschy G. and Karege F. (2005). Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. *Neuropsychobiology* 51, 234-238.
- Gharami K., Xie Y., An J.J., Tonegawa S. and Xu B. (2008). Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. *J. Neurochem.* 105, 369-379.
- Goodman L.J., Valverde J., Lim F., Geschwind M.D., Federoff H.J., Geller A.I. and Hefti F. (1996). Regulated release and polarized localization of brain-derived neurotrophic factor in hippocampal neurons. *Mol. Cell. Neurosci.* 7, 223-228.
- Gorba T. and Wahle P. (1999). Expression of TrkB and TrkC but not BDNF mRNA in neurochemically identified interneurons in rat visual cortex *in vivo* and in organotypic cultures. *Eur. J. Neurosci.* 11, 1179-1190.
- Gould E., Woolley C.S. and McEwen B.S. (1990). Short-term glucocorticoid manipulations affect neuronal morphology and survival in the adult dentate gyrus. *Neuroscience* 37, 367-375.
- Gourley S.L., Wu F.J., Kiraly D.D., Ploski J.E., Kedves A.T., Duman R.S. and Taylor J.R. (2008). Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. *Biol. Psychiatry*. 63, 353-359.
- Grimes M.L., Zhou J., Beattie E.C., Yuen E.C., Hall D.E., Valletta J.S., Topp K.S., LaVail J.H., Bunnett N.W. and Mobley W.C. (1996). Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes. *J. Neurosci.* 16, 7950-7964.
- Guilford C., Suzuki S., Kojima M., Lu B. and Zheng J.Q. (2004). Lipid rafts mediate chemotropic guidance of nerve growth cones. *Neuron* 42, 51-62.
- Ha J., Lo K.W., Myers K.R., Carr T.M., Humsi M.K., Rasoul B.A., Segal R.A. and Pfister K.K. (2008). A neuron-specific cytoplasmic dynein isoform preferentially transports TrkB signaling endosomes. *J. Cell Biol.* 181, 1027-1039.
- Hansson A.C., Sommer W., Rimondini R., Andbjør B., Strömberg I. and Fuxe K. (2003). c-fos reduces corticosterone-mediated effects on neurotrophic factor expression in the rat hippocampal CA1 region. *J. Neurosci.* 23, 6013-6022.
- Hartmann M., Heumann R. and Lessmann V. (2001). Synaptic secretion of BDNF after high-frequency stimulation of glutamatergic synapses. *EMBO J.* 20, 5887-5897.
- He J., Varma A., Weissfeld L.A. and Devaskar S.U. (2004). Postnatal glucocorticoid exposure alters the adult phenotype. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 287, R198-208.
- Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F. and Chao M.V. (1991). High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. *Nature* 350, 678-683.
- Her L.S. and Goldstein L.S. (2008). Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. *J. Neurosci.* 28, 13662-13672.
- Hering H., Lin C.C. and Sheng M. (2003). Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. *J. Neurosci.* 23, 3262-3271.
- Hetman M., Kanning K., Cavanaugh J.E. and Xia Z. (1999). Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. *J. Biol. Chem.* 274, 22569-22580.
- Ho C., Milev P., O'Leary D.S., Librant A., Andreasen N.C. and Wassink T.H. (2006). Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. *Arch. Gen. Psychiatry*. 63, 731-740.
- Hofer M., Paglisi S.R., Hohn A., Leibrock J. and Barde Y.A. (1990). Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. *EMBO J.* 9, 2459-2464.
- Hong E.J., McCord A.E. and Greenberg M.E. (2008). Neuron. A biological function for the neuronal activity-dependent component of Bdnf transcription in the development of cortical inhibition. 60, 610-624.
- Hoover B.R., Everett C.V., Sorkin A. and Zahniser N.R. (2007). Rapid regulation of dopamine transporters by tyrosine kinases in rat neuronal preparations. *J. Neurochem.* 101, 1258-1271.
- Horch H.W. and Katz L.C. (2002). BDNF release from single cells elicits local dendritic growth in nearby neurons. *Nat. Neurosci.* 5, 1177-1184.
- Horton A.C. and Ehlers M.D. (2003) Dual modes of endoplasmic reticulum-to-Golgi transport in dendrites revealed by live-cell imaging. *J. Neurosci.* 23, 6188-6199.
- Horton A.C., Rácz B., Monson E.E., Lin A.L., Weinberg R.J. and Ehlers M.D. (2005). Polarized secretory trafficking directs cargo for asymmetric dendrite growth and morphogenesis. *Neuron* 48, 757-771.
- Howe C.L., Valletta J.S., Rusnak A.S. and Mobley W.C. (2001). NGF signaling from clathrin-coated vesicles: evidence that signaling endosomes serve as a platform for the Ras-MAPK pathway. *Neuron* 32, 801-814.
- Huang E.J. and Reichardt L.F. (2003). Trk receptors: roles in neuronal signal transduction. *Annu. Rev. Biochem.* 72, 609-642.
- Huot R.L., Plotsky P.M., Lenox R.H. and McNamara R.K. (2002). Neonatal maternal separation reduces hippocampal mossy fiber density in adult Long Evans rats. *Brain Res.* 950, 52-63.
- Ibáñez C.F. (2007). Message in a bottle: long-range retrograde signaling in the nervous system. *Trends Cell Biol.* 17, 519-528.
- Jain S., Li Y., Kumar A. and Sehgal P.B. (2005). Transcriptional signaling from membrane raft-associated glucocorticoid receptor. *Biochem. Biophys. Res. Commun.* 336, 3-8.
- Jeanneveau F., Garabedian M.J. and Chao M.V. (2008). Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. *Proc. Natl. Acad. Sci. USA* 105, 4862-4867.

- Ji Y., Pang P.T., Feng L. and Lu B. (2005). Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. *Nat. Neurosci.* 8, 164-172.
- Jia Y., Zhou J., Tai Y. and Wang Y. (2007). TRPC channels promote cerebellar granule neuron survival. *Nat. Neurosci.* 10, 559-567.
- Jiang H., Guo W., Liang X. and Rao Y. (2005). Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3 β and its upstream regulators. *Cell* 120, 123-135.
- Johnson-Farley N.N., Patel K., Kim D., Cowen D.S. (2007). Interaction of FGF-2 with IGF-1 and BDNF in stimulating Akt, ERK, and neuronal survival in hippocampal cultures. *Brain Res.* 1154, 40-49.
- Jovanovic J.N., Czernik A.J., Fienberg A.A., Greengard P. and Sihra T.S. (2000). Synapsins as mediators of BDNF-enhanced neurotransmitter release. *Nat. Neurosci.* 3, 323-329.
- Kamphuis P.J.G.H., Gardoni F., Kamal A., Croiset G., Bakker J.M., Cattabeni F., Gispen W.H., van Bel F., Luca M.D. and Wiegant V.M. (2003). Long-lasting effects of neonatal dexamethasone treatment on spatial learning and hippocampal synaptic plasticity. Involvement of the NMDA receptor complex. *FASEB J.* 17, 911-913.
- Kang H. and Schuman E.M. (1995). Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. *Science* 267, 1658-1662.
- Kanning K.C., Hudson M., Amieux P.S., Wiley J.C., Bothwell M. and Schefterson L.C. (2003). Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability. *J. Neurosci.* 23, 5425-5436.
- Kaplan D.R. and Miller F.D. (2000). Neurotrophin signal transduction in the nervous system. *Curr. Opin. Neurobiol.* 10, 381-391.
- Karege F., Vaudan G., Schwald M., Perroud N. and La Harpe R. (2005). Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. *Brain Res. Mol. Brain Res.* 136, 29-37.
- Kassel O., Sancono A., Krätzschar J., Kreft B., Stassen M. and Cato A.C. (2001). Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. *EMBO J.* 20, 7108-7116.
- Kenchappa R.S., Zampieri N., Chao M.V., Barker P.A., Teng H.K., Hempstead B.L. and Carter B.D. (2006). Ligand-dependent cleavage of the P75 neurotrophin receptor is necessary for NRIF nuclear translocation and apoptosis in sympathetic neurons. *Neuron* 50, 219-232.
- Keyse S.M. (2000). Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. *Curr. Opin. Cell Biol.* 12, 186-192.
- Knable M.B., Barci B.M., Webster M.J., Meador-Woodruff J. and Torrey E.F. (2004). Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. *Mol. Psychiatry.* 9, 609-620.
- Ko M., Zou K., Minagawa H., Yu W., Gong J.S., Yanagisawa K. and Michikawa M. (2005). Cholesterol-mediated neurite outgrowth is differently regulated between cortical and hippocampal neurons. *J. Biol. Chem.* 280, 42759-42765.
- Kohara K., Kitamura A., Morishima M. and Tsumoto T. (2001). Activity-dependent transfer of brain-derived neurotrophic factor to postsynaptic neurons. *Science* 291, 2419-2423.
- Kojima M., Takei N., Numakawa T., Ishikawa Y., Suzuki S., Matsumoto T., Katoh-Semba R., Nawa H., and Hatanaka H. (2001). Biological characterization and optical imaging of brain-derived neurotrophic factor-green fluorescent protein suggest an activity-dependent local release of brain-derived neurotrophic factor in neurites of cultured hippocampal neurons. *J. Neurosci. Res.* 64, 1-10.
- Kolarow R., Brigadski T. and Lessmann V. (2007). Postsynaptic secretion of BDNF and NT-3 from hippocampal neurons depends on calcium calmodulin kinase II signaling and proceeds via delayed fusion pore opening. *J. Neurosci.* 27, 10350-10364.
- Komatsuzaki Y., Murakami G., Tsurugizawa T., Mukai H., Tanabe N., Mitsuhashi K., Kawata M., Kimoto T., Oishi Y. and Kawato S. (2005). Rapid spinogenesis of pyramidal neurons induced by activation of glucocorticoid receptors in adult male rat hippocampus. *Biochem. Biophys. Res. Commun.* 335, 1002-1007.
- Korade Z., Mi Z., Portugal C. and Schor N.F. (2007). Expression and p75 neurotrophin receptor dependence of cholesterol synthetic enzymes in adult mouse brain. *Neurobiol. Aging* 28, 1522-1531.
- Korade Z., Kenchappa R.S., Mirnic K. and Carter B.D. (2008). NRIF is a regulator of neuronal cholesterol biosynthesis genes. *J. Mol. Neurosci.*
- Korte M., Griesbeck O., Gravel C., Carroll P., Staiger V., Thoenen H. and Bonhoeffer T. (1996). Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice. *Proc. Natl. Acad. Sci. USA* 93, 12547-12552.
- Kumamaru E., Numakawa T., Adachi N., Yagasaki Y., Izumi A., Niyaz M., Kudo M. and Kunugi H. (2008). Glucocorticoid prevents brain-derived neurotrophic factor-mediated maturation of synaptic function in developing hippocampal neurons through reduction in the activity of mitogen-activated protein kinase. *Mol. Endocrinol.* 22, 546-558.
- Kumar V., Zhang M.X., Swank M.W., Kunz J. and Wu G.Y. (2005). Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. *J. Neurosci.* 25, 11288-11299.
- Kunugi H., Ida I., Owashi T., Kimura M., Inoue Y., Nakagawa S., Yabana T., Urushibara T., Kanai R., Aihara M., Yuuki N., Otsubo T., Oshima A., Kudo K., Inoue T., Kitaichi Y., Shirakawa O., Isogawa K., Nagayama H., Kamijima K., Nanko S., Kanba S., Higuchi T. and Mikuni M. (2006). Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a Multicenter Study. *Neuropsychopharmacology* 31, 212-220.
- Kuruville R., Ye H. and Ginty D.D. (2000). Spatially and functionally distinct roles of the PI3-K effector pathway during NGF signaling in sympathetic neurons. *Neuron* 27, 499-512.
- Lang T., Bruns D., Wenzel D., Riedel D., Holroyd P., Thiele C. and Jahn R. (2001). SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. *EMBO J.* 20, 2202-2213.
- Lee R., Kermani P., Teng K.K. and Hempstead B.L. (2001). Regulation of cell survival by secreted proneurotrophins. *Science* 294, 1945-1948.
- Lessmann V., Gottmann K. and Heumann R. (1994). BDNF and NT-4/5 enhance glutamatergic synaptic transmission in cultured hippocampal neurones. *Neuroreport* 6, 21-25.
- Lessmann V., Gottmann K. and Malcangio M. (2003). Neurotrophin secretion: current facts and future prospects. *Prog. Neurobiol.* 69, 341-374.
- Levine E.S., Dreyfus C.F., Black I.B. and Plummer M.R. (1995). Brain-derived neurotrophic factor rapidly enhances synaptic transmission in hippocampal neurons via postsynaptic tyrosine kinase receptors. *Proc. Natl. Acad. Sci. USA* 92, 8074-8077.

BDNF function and signaling

- Levine E.S., Crozier R.A., Black I.B. and Plummer M.R. (1998). Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. *Proc. Natl. Acad. Sci. USA* 95, 10235-10239.
- Li Y., Jia Y.C., Cui K., Li N., Zheng Z.Y., Wang Y.Z. and Yuan X.B. (2005). Essential role of TRPC channels in the guidance of nerve growth cones by brain-derived neurotrophic factor. *Nature* 434, 894-898.
- Li Y.X., Xu Y., Ju D., Lester H.A., Davidson N. and Schuman E.M. (1998). Expression of a dominant negative TrkB receptor, T1, reveals a requirement for presynaptic signaling in BDNF-induced synaptic potentiation in cultured hippocampal neurons. *Proc. Natl. Acad. Sci. USA* 95, 10884-10889.
- Lin Y., Bloodgood B.L., Hauser J.L., Lapan A.D., Koon A.C., Kim T.K., Hu L.S., Malik A.N. and Greenberg M.E. (2008). Activity-dependent regulation of inhibitory synapse development by Npas4. *Nature* 455, 1198-1204.
- Lindholm D., Castren E., Berzaghi M., Blochl A. and Thoenen H. (1994). Activity-dependent and hormonal regulation of neurotrophin mRNA levels in the brain - implications for neuronal plasticity. *J. Neurobiol.* 25, 1362-1372.
- Lissin D.V., Carroll R.C., Nicoll R.A., Malenka R.C. and von Zastrow M. (1999). Rapid, activation-induced redistribution of ionotropic glutamate receptors in cultured hippocampal neurons. *J. Neurosci.* 19, 1263-1272.
- Liu D., Diorio J., Tannenbaum B., Caldji C., Francis D., Freedman A., Sharma S., Pearson D., Plotsky P.M. and Meaney M.J. (1997). Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. *Science* 277, 1659-1662.
- Liu D., Diorio J., Day J.C., Francis D.D. and Meaney M.J. (2000). Maternal care, hippocampal synaptogenesis and cognitive development in rats. *Nat. Neurosci.* 3, 799-806.
- Liu Q.R., Lu L., Zhu X.G., Gong J.P., Shaham Y. and Uhl G.R. (2006). Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. *Brain Res.* 1067, 1-12.
- Lou H., Kim S.K., Zaitsev E., Snell C.R., Lu B. and Loh Y.P. (2005). Sorting and activity-dependent secretion of BDNF require interaction of a specific motif with the sorting receptor carboxypeptidase E. *Neuron* 45, 245-255.
- Löwenberg M., Verhaar A.P., van den Brink G.R. and Hommes D.W. (2007). Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. *Trends Mol. Med.* 13, 158-163.
- Lu B. (2003). BDNF and activity-dependent synaptic modulation. *Learn. Mem.* 10, 86-98.
- Lu B., Pang P.T. and Woo N.H. (2005). The yin and yang of neurotrophin action. *Nat. Rev. Neurosci.* 6, 603-614.
- Lu Y., Christian K. and Lu B. (2008). BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? *Neurobiol. Learn. Mem.* 89, 312-323.
- Marini A.M., Rabin S.J., Lipsky R.H. and Mocchetti I. (1998). Activity-dependent release of brain-derived neurotrophic factor underlies the neuroprotective effect of N-methyl-D-aspartate. *J. Biol. Chem.* 273, 29394-29399.
- Martin M.G., Perga S., Trovò L., Rasola A., Holm P., Rantamäki T., Harkany T., Castrén E., Chiara F. and Dotti CG. (2008). Cholesterol loss enhances TrkB signaling in hippocampal neurons aging *in vitro*. *Mol. Biol. Cell* 19, 2101-2112.
- Martínez-Turrillas R., Del Río J. and Frechilla D. (2005). Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment. *Neuropharmacology* 49, 1178-1188.
- Matsumoto T., Numakawa T., Adachi N., Yokomaku D., Yamagishi S., Takei N. and Hatanaka H. (2001). Brain-derived neurotrophic factor enhances depolarization-evoked glutamate release in cultured cortical neurons. *J. Neurochem.* 79, 522-530.
- Matsumoto T., Numakawa T., Yokomaku D., Adachi N., Yamagishi S., Numakawa Y., Kunugi H. and Taguchi T. (2006). Brain-derived neurotrophic factor-induced potentiation of glutamate and GABA release: different dependency on signaling pathways and neuronal activity. *Mol. Cell. Neurosci.* 31, 70-84.
- Matsumoto T., Rauskolb S., Polack M., Klose J., Kolbeck R., Korte M. and Barde Y.A. (2008). Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. *Nat. Neurosci.* 11, 131-133.
- Matthews L., Berry A., Ohanian V., Ohanian J., Garside H. and Ray D. (2008). Caveolin mediates rapid glucocorticoid effects and couples glucocorticoid action to the antiproliferative program. *Mol. Endocrinol.* 22, 1320-1330.
- Mattson M.P. (2008). Glutamate and neurotrophic factors in neuronal plasticity and disease. *Ann. NY Acad. Sci.* 1144, 97-112.
- Mauch D.H., Nägler K., Schumacher S., Göritz C., Müller E.C., Otto A. and Priefer F.W. (2001). CNS synaptogenesis promoted by glia-derived cholesterol. *Science* 294, 1354-1357.
- McAllister A.K., Lo D.C. and Katz L.C. (1995). Neurotrophins regulate dendritic growth in developing visual cortex. *Neuron* 15, 791-803.
- McAllister A.K., Katz L.C. and Lo D.C. (1996). Neurotrophin regulation of cortical dendritic growth requires activity. *Neuron* 17, 1057-1064.
- McEwen B.S. (2005). Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. *Metabolism* 54, 20-23.
- Mirescu C., Peters J.D. and Gould E. (2004). Early life experience alters response of adult neurogenesis to stress. *Nat. Neurosci.* 7, 841-846.
- Mizoguchi K., Ishige A., Takeda S., Aburada M. and Tabira T. (2004). Endogenous glucocorticoids are essential for maintaining prefrontal cortical cognitive function. *J. Neurosci.* 24, 5492-5499.
- Mowla S.J., Farhadi H.F., Pareek S., Atwal J.K., Morris S.J., Seidah N.G. and Murphy R.A. (2001). Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor. *J. Biol. Chem.* 276, 12660-12666.
- Nagappan G. and Lu B. (2005). Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications. *Trends Neurosci.* 28, 464-471.
- Nagappan G., Zaitsev E., Senatorov V.V. Jr, Yang J., Hempstead B.L. and Lu B. (2009). Control of extracellular cleavage of ProBDNF by high frequency neuronal activity. *Proc. Natl. Acad. Sci. USA* 106, 1267-1272.
- Nair A., Vadodaria K.C., Banerjee S.B., Benekareddy M., Dias B.G., Duman R.S. and Valdivya V.A. (2007). Stressor-specific regulation of distinct brain-derived neurotrophic factor transcripts and cyclic AMP response element-binding protein expression in the postnatal and adult rat hippocampus. *Neuropsychopharmacology* 32, 1504-1519.
- Nakata H. and Nakamura S. (2007). Brain-derived neurotrophic factor regulates AMPA receptor trafficking to post-synaptic densities via IP3R and TRPC calcium signaling. *FEBS Lett.* 581, 2047-2054.
- Narisawa-Saito M., Silva A.J., Yamaguchi T., Hayashi T., Yamamoto T. and Nawa H. (1999). Growth factor-mediated Fyn signaling regulates alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor expression in rodent neocortical neurons.

- Proc. Natl. Acad. Sci. USA 96, 2461-2466.
- Nieweg K., Schaller H. and Pfrieger F.W. (2009). Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. *J. Neurochem.* 109, 125-134.
- Nishiyama M., von Schimmelmann M.J., Togashi K., Findley W.M. and Hong K. (2008). Membrane potential shifts caused by diffusible guidance signals direct growth-cone turning. *Nat. Neurosci.* 11, 762-771.
- Numakawa T., Matsumoto T., Adachi N., Yokomaku D., Kojima M., Takei N. and Hatanaka H. (2001). Brain-derived neurotrophic factor triggers a rapid glutamate release through increase of intracellular Ca(2+) and Na(+) in cultured cerebellar neurons. *J. Neurosci. Res.* 66, 96-108.
- Numakawa T., Yamagishi S., Adachi N., Matsumoto T., Yokomaku D., Yamada M. and Hatanaka H. (2002a). Brain-derived neurotrophic factor-induced potentiation of Ca(2+) oscillations in developing cortical neurons. *J. Biol. Chem.* 277, 6520-6529.
- Numakawa T., Yokomaku D., Kiyosue K., Adachi N., Matsumoto T., Numakawa Y., Taguchi T., Hatanaka H. and Yamada M. (2002b). Basic fibroblast growth factor evokes a rapid glutamate release through activation of the MAPK pathway in cultured cortical neurons. *J. Biol. Chem.* 277, 28861-28869.
- Numakawa T., Ishimoto T., Suzuki S., Numakawa Y., Adachi N., Matsumoto T., Yokomaku D., Koshimizu H., Fujimori K.E., Hashimoto R., Taguchi T. and Kunugi H. (2004). Neuronal roles of the integrin-associated protein (IAP/CD47) in developing cortical neurons. *J. Biol. Chem.* 279, 43245-43253.
- Numakawa Y., Matsumoto T., Yokomaku D., Taguchi T., Niki E., Hatanaka H., Kunugi H. and Numakawa T. (2007). 17beta-estradiol protects cortical neurons against oxidative stress-induced cell death through reduction in the activity of mitogen-activated protein kinase and in the accumulation of intracellular calcium. *Endocrinology* 148, 627-637.
- Numakawa T., Kumamaru E., Adachi N., Yagasaki Y., Izumi A. and Kunugi H. (2009). Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. *Proc. Natl. Acad. Sci. USA* 106, 647-652.
- Obara Y., Horgan A.M. and Stork P.J. (2007). The requirement of Ras and Rap1 for the activation of ERKs by cAMP, PACAP, and KCl in cerebellar granule cells. *J. Neurochem.* 101, 470-482.
- Obradovic D., Gronemeyer H., Lutz B. and Rein T. (2006). Cross-talk of vitamin D and glucocorticoids in hippocampal cells. *J. Neurochem.* 96, 500-509.
- Ozdinler P.H. and Macklis J.D. (2006). IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. *Nat. Neurosci.* 9, 1371-1381.
- Pang P.T., Teng H.K., Zaitsev E., Woo N.T., Sakata K., Zhen S., Teng K.K., Yung W.H., Hempstead B.L. and Lu B. (2004). Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. *Science* 306, 487-491.
- Paredes D., Granholm A.C. and Bickford P.C. (2007). Effects of NGF and BDNF on baseline glutamate and dopamine release in the hippocampal formation of the adult rat. *Brain Res.* 1141, 56-64.
- Patterson S.L., Abel T., Deuel T.A., Martin K.C., Rose J.C. and Kandel E.R. (1996). Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. *Neuron* 16, 1137-1145.
- Pereira D.B., Rebola N., Rodrigues R.J., Cunha R.A., Carvalho A.P. and Duarte C.B. (2006). TrkB receptors modulation of glutamate release is limited to a subset of nerve terminals in the adult rat hippocampus. *J. Neurosci. Res.* 83, 832-844.
- Pereira D.B. and Chao M.V. (2007). The tyrosine kinase Fyn determines the localization of TrkB receptors in lipid rafts. *J. Neurosci.* 27, 4859-4869.
- Peters A. and Kaiserman-Abramof I.R. (1970). The small pyramidal neuron of the rat cerebral cortex. The perikaryon, dendrites and spines. *Am. J. Anat.* 127, 321-355.
- Pfrieger F.W. (2003). Cholesterol homeostasis and function in neurons of the central nervous system. *Cell. Mol. Life Sci.* 60, 1158-1171.
- Pillai A., Veeranan-Karmegam R., Dhandapani K.M. and Mahadik S.P. (2008). Cystamine prevents haloperidol-induced decrease of BDNF/TrkB signaling in mouse frontal cortex. *J. Neurochem.* 107, 941-951.
- Poo M.M. (2001). Neurotrophins as synaptic modulators. *Nat. Rev. Neurosci.* 2, 24-32.
- Rocamora N., Welker E., Pascual M. and Soriano E. (1996). Upregulation of BDNF mRNA in the barrel cortex of adult mice after sensory stimulation. *J. Neurosci.* 16, 4411-4419.
- Roceri M., Hendriks W., Racagni G., Ellenbroek B.A. and Riva M.A. (2002). Early maternal deprivation reduces the expression of BDNF and NMDA receptor subunits in rat hippocampus. *Mol. Psychiatry* 7, 609-616.
- Rösch H., Schweigreiter R., Bonhoeffer T., Barde Y.A. and Korte M. (2005). The neurotrophin receptor p75NTR modulates long-term depression and regulates the expression of AMPA receptor subunits in the hippocampus. *Proc. Natl. Acad. Sci. USA* 102, 7362-7367.
- Rössler O.G., Giehl K.M. and Thiel G. (2004). Neuroprotection of immortalized hippocampal neurones by brain-derived neurotrophic factor and Raf-1 protein kinase: role of extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase. *J. Neurochem.* 88, 1240-1252.
- Sadakata T., Kakegawa W., Mizoguchi A., Washida M., Katoh-Semba R., Shutoh F., Okamoto T., Nakashima H., Kimura K., Tanaka M., Sekine Y., Itohara S., Yuzaki M., Nagao S. and Furuichi T. (2007). Impaired cerebellar development and function in mice lacking CAPS2, a protein involved in neurotrophin release. *J. Neurosci.* 27, 2472-2482.
- Sala R., Viegi A., Rossi F.M., Pizzorusso T., Bonanno G., Raiteri M. and Maffei L. (1998). Nerve growth factor and brain-derived neurotrophic factor increase neurotransmitter release in the rat visual cortex. *Eur. J. Neurosci.* 10, 2185-2191.
- Santi S., Cappello S., Riccio M., Bergami M., Alicardi G., Schenk U., Matteoli M. and Canossa M. (2006). Hippocampal neurons recycle BDNF for activity-dependent secretion and LTP maintenance. *EMBO J.* 25, 4372-4380.
- Schaaf M.J., De Kloet E.R. and Vreugdenhil E. (2000). Corticosterone effects on BDNF expression in the hippocampus. Implications for memory formation. *Stress* 3, 201-208.
- Schäbitz W.R., Sommer C., Zoder W., Kiessling M., Schwaninger M. and Schwab S. (2000). Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. *Stroke* 31, 2212-2217.
- Scharfman H.E. and MacLusky N.J. (2006). Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS. *Front Neuroendocrinol.* 27, 415-435.